ࡱ> \_YZ[ 0bjbj >4 R!R!R!R!R!4!!!h!,#|!]$$%%%L&b& n&\\\\\\\$bfe]R!v&L&L&v&v&]R!R!%%4]D5D5D5v&|R!%R!%[pD5v&\D5D56McP %0MS83)Nm[]0]N f. f8oPoP fR!Rv&v&D5v&v&v&v&v&]]4v&v&v&]v&v&v&v& fv&v&v&v&v&v&v&v&v&  : Protocol for the Examination of Specimens From Patients With Primary Carcinoma of the Vulva Version: Vulva 4.1.0.0Protocol Posting Date: August 2018Includes pTNM requirements from the 8th Edition, AJCC Staging Manual, and 2015 FIGO Cancer Report For accreditation purposes, this protocol should be used for the following procedures AND tumor types: ProcedureDescriptionResectionIncludes vulvectomy (with or without removal of other organs and tissues)Tumor TypeDescriptionCarcinomaIncludes squamous cell carcinoma, adenocarcinoma and variants, carcinosarcoma, neuroendocrine carcinoma, and mixed epithelial neuroendocrine tumors  This protocol is NOT required for accreditation purposes for the following: ProcedureBiopsyPrimary resection specimen with no residual cancer (eg, following neoadjuvant therapy)Cytologic specimens The following tumor types should NOT be reported using this protocol: Tumor TypeMelanoma (consider the Skin Melanoma protocol)Lymphoma (consider the Hodgkin or non-Hodgkin Lymphoma protocols)Sarcoma (consider the Soft Tissue protocol) Authors Saeid Movahedi-Lankarani, MD*; Uma Krishnamurti, MD, PhD*; Debra A. Bell, MD; George G. Birdsong, MD; Charles V. Biscotti, MD; Christopher N. Chapman Jr, MD; Veronica Klepeis, MD, PhD; Anthony G. Montag, MD With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees. * Denotes primary authors. All other contributing authors are listed alphabetically. Accreditation Requirements This protocol can be utilized for a variety of procedures and tumor types for clinical care purposes. For accreditation purposes, only the definitive primary cancer resection specimen is required to have the core and conditional data elements reported in a synoptic format. Core data elements are required in reports to adequately describe appropriate malignancies. For accreditation purposes, essential data elements must be reported in all instances, even if the response is not applicable or cannot be determined. Conditional data elements are only required to be reported if applicable as delineated in the protocol. For instance, the total number of lymph nodes examined must be reported, but only if nodes are present in the specimen. Optional data elements are identified with + and although not required for CAP accreditation purposes, may be considered for reporting as determined by local practice standards. The use of this protocol is not required for recurrent tumors or for metastatic tumors that are resected at a different time than the primary tumor. Use of this protocol is also not required for pathology reviews performed at a second institution (ie, secondary consultation, second opinion, or review of outside case at second institution). Synoptic Reporting All core and conditionally required data elements outlined on the surgical case summary from this cancer protocol must be displayed in synoptic report format. Synoptic format is defined as: Data element: followed by its answer (response), outline format without the paired "Data element: Response" format is NOT considered synoptic. The data element should be represented in the report as it is listed in the case summary. The response for any data element may be modified from those listed in the case summary, including Cannot be determined if appropriate. Each diagnostic parameter pair (Data element: Response) is listed on a separate line or in a tabular format to achieve visual separation. The following exceptions are allowed to be listed on one line: Anatomic site or specimen, laterality, and procedure Pathologic Stage Classification (pTNM) elements Negative margins, as long as all negative margins are specifically enumerated where applicable The synoptic portion of the report can appear in the diagnosis section of the pathology report, at the end of the report or in a separate section, but all Data element: Responses must be listed together in one location Organizations and pathologists may choose to list the required elements in any order, use additional methods in order to enhance or achieve visual separation, or add optional items within the synoptic report. The report may have required elements in a summary format elsewhere in the report IN ADDITION TO but not as replacement for the synoptic report ie, all required elements must be in the synoptic portion of the report in the format defined above. CAP Laboratory Accreditation Program Protocol Required Use Date: April 2019 CAP Vulva Protocol Summary of Changes Version 4.1.0.0 The following data elements were modified: Regional Lymph Nodes - Revised the format to clarify reporting involved and uninvolved nodes Surgical Pathology Cancer Case Summary Protocol posting date: August 2018 VULVA: Select a single response unless otherwise indicated. Procedure (Note A) ___ Local excision ___ Wide excision ___ Partial vulvectomy ___ Total vulvectomy ___ Radical vulvectomy ___ Other (specify): ____________________________ ___ Not specified Tumor Site (select all that apply) ___ Right vulva + ___ Labium majus + ___ Labium minus + ___ Bartholin gland ___ Left vulva + ___ Labium majus + ___ Labium minus + ___ Bartholin gland ___ Clitoris ___ Other (specify): _____________________________ ___ Not specified Tumor Size (Note B) Greatest dimension (centimeters): ___ cm + Additional dimensions (centimeters): ___ x ___ cm ___ Cannot be determined (explain): ______________________________ Tumor Focality ___ Unifocal ___ Multifocal ___ Cannot be determined (explain): ______________________________ ___ Not specified Histologic Type (Notes C and D) ___ Squamous cell carcinoma, NOS ___ Squamous cell carcinoma, keratinizing ___ Squamous cell carcinoma, nonkeratinizing ___ Squamous cell carcinoma, basaloid ___ Squamous cell carcinoma, verrucous ___ Squamous cell carcinoma, warty ___ Squamous cell carcinoma, papillary ___ Adenocarcinoma, NOS ___ Adenocarcinoma, mammary gland type ___ Adenocarcinoma, skene gland type ___ Adenocarcinoma, sweat gland type ___ Adenocarcinoma, intestinal type ___ Adenocarcinoma, with associated Paget disease ___ Adenosquamous carcinoma ___ Transitional cell carcinoma ___ Adenoid cystic carcinoma ___ Adenoid basal carcinoma ___ Small cell neuroendocrine carcinoma ___ Large cell neuroendocrine carcinoma ___ Undifferentiated carcinoma ___ Other histologic type not listed (specify): _________________________ ___ Carcinoma, type cannot be determined Histologic Grade ___ G1: Well differentiated ___ G2: Moderately differentiated ___ G3: Poorly differentiated ___ G4: Undifferentiated ___ Other (specify): ____________________________ ___ GX: Cannot be assessed ___ Not applicable Depth of Invasion (Note E) Specify depth of invasion (millimeters): ___ mm ___ Cannot be determined (explain): __________________________ + Tumor Border (Note F) + ___ Pushing + ___ Infiltrating Other Tissue/ Organ Involvement (select all that apply) Note: Any organ not selected is either not involved or was not submitted. ___ Not applicable ___ Not identified ___ Vagina, lower one-third ___ Vagina, upper two-thirds ___ Urethra, lower one-third ___ Urethra, upper two-thirds ___ Anus ___ Bladder mucosa ___ Rectal mucosa ___ Pelvic bone ___ Other organs/tissue (specify): ________________ ___ Cannot be determined (explain): _________________________ Margins# Peripheral Margin (select all that apply) ___ Cannot be assessed (explain): __________________________ ___ Uninvolved by invasive carcinoma + Distance of invasive carcinoma from margin (millimeters): ___ mm + Specify location: ____________________________ ___ Involved by invasive carcinoma Specify location(s), if possible: ____________________________ ___ Uninvolved by intraepithelial neoplasia ___ Involved by high-grade squamous intraepithelial lesion (VIN 2-3) + Specify location(s): ____________________________ ___ Involved by vulvar intraepithelial neoplasia, differentiated (simplex) type (dVIN) + Specify location(s): ____________________________ ___ Involved by Paget disease + Specify location(s): ____________________________ Deep Margin (select all that apply) ___ Cannot be assessed (explain): __________________________ ___ Uninvolved by invasive carcinoma + Distance of invasive carcinoma from margin (millimeters): ___ mm + Specify location: ____________________________ ___ Involved by invasive carcinoma Specify location(s), if possible: ____________________________ ___ Uninvolved by intraepithelial neoplasia ___ Involved by high-grade squamous intraepithelial lesion (VIN 2-3) + Specify location(s): ____________________________ ___ Involved by vulvar intraepithelial neoplasia, differentiated (simplex) type (dVIN) + Specify location(s): ____________________________ ___ Involved by Paget disease + Specify location(s): ____________________________ # High-grade squamous intraepithelial lesion (VIN 2-3), dVIN, and/or Paget disease should be reported if present, even if margin is involved by invasive carcinoma. Lymphovascular Invasion (Note G) ___ Not identified ___ Present ___ Cannot be determined (explain): _____________________________ Regional Lymph Nodes Note: Only inguinal and femoral nodes are considered regional lymph nodes. Any other involved nodes should be categorized as metastases (pM1) and be commented on in the distant metastasis section. Presence of isolated tumor cells no greater than 0.2 mm in regional lymph node(s) is considered N0 (i+). ___ No lymph nodes submitted or found Lymph Node Examination (required only if lymph nodes are present in the specimen) ___ All lymph nodes negative for tumor cells ___ Positive for tumor cells (select all that apply) Number of Nodes with Metastasis 5 mm or Greater: ____ Number of Nodes with Metastasis Less than 5 mm (excludes isolated tumor cells): ____ Number of Nodes with Isolated Tumor Cells (0.2 mm or less) (if applicable): ____ Number cannot be determined (explain): ____________________________ Note: Reporting the number of lymph nodes with isolated tumor cells is required only in the absence of metastasis greater than 0.2 mm in other lymph nodes. + Nodal Site(s) with Tumor Cells (specify): _________________________ Additional Lymph Node Findings (select all that apply) (required only if applicable) (Note I) ___ None identified ___ Extranodal extension ___ Fixed/ulcerated nodes ___ Other (specify): ____________________________ ___ Cannot be determined (explain): _____________________________ Total Number of Lymph Nodes Examined: ____ ___ Number cannot be determined (explain): ____________________________ + Specify Site(s): ____________________________ Number of Sentinel Nodes Examined (if applicable): ____ ___ Number cannot be determined (explain): ____________________________ Pathologic Stage Classification (pTNM, AJCC 8th Edition) (Note H) Note: Reporting of pT, pN, and (when applicable) pM categories is based on information available to the pathologist at the time the report is issued. Only the applicable T, N, or M category is required for reporting; their definitions need not be included in the report. The categories (with modifiers when applicable) can be listed on 1 line or more than 1 line. TNM Descriptors (required only if applicable) (select all that apply) ___ m (multiple primary tumors) ___ r (recurrent) ___ y (posttreatment) Primary Tumor (pT) ___ pTX: Primary tumor cannot be assessed ___ pT0: No evidence of primary tumor ___ pT1: Tumor confined to the vulva and / or perineum# ___ pT1a: Lesions 2 cm or less, confined to the vulva and/or perineum, and with stromal invasion of 1.0 mm or less ## ___ pT1b: Lesions more than 2 cm, or any size with stromal invasion more than 1.0 mm, confined to the vulva and/or perineum ___ pT2: Tumor of any size with extension to adjacent perineal structures (lower/distal third of the urethra, lower/distal third of the vagina, anal involvement) ___ pT3: Tumor of any size with extension to any of the following: upper/proximal two-thirds of the urethra, upper/proximal two-thirds of the vagina, bladder mucosa, or rectal mucosa, or fixed to pelvic bone # Multifocal lesions should be designated as such. The largest lesion or the lesion with the greatest depth of invasion will be the target lesion identified to address the highest pT stage. Depth of invasion is defined as the measurement of the tumor from the epithelialstromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion. ## Note: The LAST definition of superficial invasive squamous cell carcinoma (SISCCA) conforms to AJCC pT1a/FIGO IA Regional Lymph Nodes (pN) (select all that apply) + Modifier + ___ (sn) + ___ (sn)(i-) + ___ (sn)(i+) Category (pN) ___ pNX: Regional lymph nodes cannot be assessed ___ pN0: No regional lymph node metastasis ___ pN0(i+): Isolated tumor cells in regional lymph node(s) no greater than 0.2 mm ___ pN1: Regional lymph node metastasis with one or two lymph node metastases each less than 5 mm, or one lymph node metastasis e" 5 mm ___ pN1a: One or two lymph node metastasis each less than 5 mm# ___ pN1b: One lymph node metastasis e" 5 mm ___ pN2: Regional lymph node metastasis with three or more lymph node metastases each less than 5 mm, or two or more lymph node metastases e" 5 mm, or lymph node(s) with extranodal extension ___ pN2a: Three or more lymph node metastases each less than 5 mm# ___ pN2b: Two or more lymph node metastases e" 5 mm ___ pN2c: Lymph node(s) with extranodal extension ___ pN3: Fixed or ulcerated regional lymph node metastasis # Includes micrometastasis, N1mi and N2mi.The site, size, and laterality of lymph node metastases should be recorded. Distant Metastasis (pM) (required only if confirmed pathologically in this case) ___ pM1: Distant metastasis (including pelvic lymph node metastasis)# Specify site(s), if known: ____________________________ # Internal iliac/hypogastric, external iliac, and common iliac lymph nodes are considered distant metastasis. + FIGO Stage (2015 FIGO Cancer Report) +___ I: Tumor confined to the vulva +___ IA: Lesions d"2 cm in size, confined to the vulva or perineum and with stromal invasion d"1.0 mm, no nodal metastasis# +___ IB: Lesions >2 cm in size or with stromal invasion >1.0 mm, confined to the vulva and/or perineum, with negative nodes +___ II: Tumor of any size with extension to adjacent perineal structures (lower third of urethra, lower third of vagina, anus) with negative nodes + ___ III: Tumor of any size with or without extension to adjacent perineal structures (lower third of urethra, lower third of vagina, anus) with positive inguinofemoral nodes +___ IIIA: With 1 lymph node metastasis (e"5 mm) +___ IIIA: With 1 to 2 lymph node metastasis(es) (<5 mm) +___ IIIB: With 2 or more lymph node metastases (e"5 mm) +___ IIIB: With 3 or more lymph node metastases (<5 mm) +___ IIIC: With positive nodes with extracapsular spread + ___ IV: Tumor invades other regional (upper two-thirds urethra, upper two-thirds vagina), or distant structures +___ IVA: Tumor invades any of the following: upper urethral and/or vaginal mucosa, bladder mucosa, rectal mucosa, or fixed to pelvic bone, or fixed or ulcerated inguino-femoral lymph nodes +___ IVB: Any distant metastasis including pelvic lymph nodes # Note: The LAST definition of superficial invasive squamous cell carcinoma (SISCCA) conforms to AJCC pT1a/FIGO IA. + Additional Pathologic Findings (select all that apply) (Note I) + ___ None identified + ___ Condyloma accuminatum + ___ High grade squamous intraepithelial lesion (VIN 2-3) + ___ Low grade squamous intraepithelial lesion (VIN 1) + ___ Vulvar intraepithelial neoplasia, differentiated (simplex) type (dVIN) + ___ Lichen sclerosus + ___ Other (specify): ___________________________ + Comment(s) Explanatory Notes A. Suggestions for Sampling of Tissue Removed for Diagnosis or Treatment of Vulvar Carcinoma Tumor Sections taken will vary with procedure, as designated by the surgeon.1 Sections to include the following should be taken (if appropriate): Tumor, representative sections, including site of deepest invasion and interface of tumor with adjacent epithelium Resection margins Sections of abnormal epithelium or other tissue remote from tumor Sections of areas(s) marked by surgeon Sections of prior biopsy or resection site of tumor if no tumor present grossly Lymph Nodes The femoral and inguinal lymph nodes are the sites of regional spread.1,2 When inguinal-femoral lymphadenectomy is performed, 6 or more lymph nodes will normally be included1,2; 1 or more sections of all lymph nodes identified should be taken, depending on presence or absence of gross tumor as well as size of lymph node. In addition, sections to confirm presence or absence of extranodal extension should be taken. Other Organs and Tissues Other organs and tissues may be submitted with the vulva specimen. Sections to include the following should be taken (if appropriate): Sections to demonstrate presence or absence of tumor Sections to demonstrate its relation, if present, to vulvar tumor (contiguous or metastatic) Sections of other lesions, if present Resection margins If frozen section analysis was performed, those tissue fragment(s) should be submitted. B. Size of Tumor Assessment of gross size of the tumor is important for staging. The tumor should be accurately measured to determine if its maximum dimension is d"2 cm or >2 cm. C. Etiology/Pathogenesis Two pathways have been elucidated in the pathogenesis of invasive vulvar carcinoma. 5-7 The first pathway involves classic vulvar intraepithelial neoplasia (VIN), which is associated with high-risk human papillomavirus (HPV) subtypes (16 > 18) and is histologically similar to dysplasia seen in the cervix. It tends to be multifocal and more common in younger women, with a relatively low risk of progression into an invasive squamous cell carcinoma. It is usually diffusely positive with p16 immunostain (reflecting HPV association). The associated invasive component is often basaloid or warty in morphology. The second pathway is referred to as differentiated or simplex VIN (dVIN). dVIN is not associated with HPV, but instead with vulvar dystrophy such as lichen sclerosus, lichen simplex chronicus, and squamous cell hyperplasia. The morphologic features are more subtle, with atypia noted in the parabasal cells. The associated invasive component is keratinizing and can be associated with p53 mutations. This subtype usually occurs in older women. Of note, overlap does exist between the 2 pathways, with some tumors exhibiting morphologic and/or clinical features of each. Keratinizing Squamous CarcinomaBasaloid Squamous Carcinoma PrevalenceMore common (approximately 80%)Less common (approximately 20%)AgeOlder femalesYounger femalesDistributionUsually unifocal, may be multifocalOften multifocalAssociation with multifocal lower genital tract neoplasiaRareCommonMorphologyKeratinizingWartyAssociated vulvar intraepithelial neoplasia (VIN)Uncommon: differentiated typeCommon: classic typeAssociation with high risk human papillomavirus (HPV)NoYes Type 16>18Association with vulvar dystrophyCommonRareImmunohistochemistryp53: Some cases positive p16: Negative or focally positive at stromal interfacep53: Negative p16: PositiveAdapted from McCluggage.5 D. Histologic Type The following is an abbreviated, slightly modified version of the World Health Organization (WHO) classification of histologic types of malignant and premalignant vulvar epithelial tumors.3,9,10 WHO and Lower Anogenital Squamous Terminology (LAST) Classification of Vulvar Epithelial Tumors and Related Lesions Squamous Intraepithelial Lesions Low-grade squamous intraepithelial lesion (VIN 1) High-grade squamous intraepithelial lesion (VIN 2-3) Differentiated (simplex) vulvar intraepithelial neoplasia (dVIN) Invasive Carcinomas Squamous cell carcinoma Superficially invasive (LAST classification, not WHO)11 Keratinizing Nonkeratinizing Basaloid Warty Verrucous Glandular Tumors Invasive Paget disease/Adenocarcinoma with associated Paget disease Bartholin gland tumors Adenocarcinoma Squamous cell carcinoma Adenoid cystic carcinoma Adenosquamous carcinoma Transitional cell carcinoma Adenocarcinoma Mammary gland type Skene gland origin Sweat gland type Intestinal type Neuroendocrine Tumors Small cell neuroendocrine carcinoma Large cell neuroendocrine carcinoma Merkel cell carcinoma Undifferentiated carcinoma E. Depth of Invasion Tumor thickness and depth of invasion are separate measurements. Tumor thickness of a squamous cell carcinoma is measured in millimeters from the surface of the tumor or, if there is surface keratinization, from the bottom of the granular layer, to the deepest point of invasion.3,4 Tumor thickness is NOT a parameter used in staging. The depth of invasion of squamous cell carcinoma is defined as the measurement in millimeters from the epithelial-stromal junction of the adjacent, most superficial dermal papilla to the deepest point of invasion.2-4 This parameter is important for tumor staging, especially for small tumors. F. Tumor Growth Pattern Vulvar squamous cell carcinomas can generally be separated into those tumors that have a predominately infiltrating (finger-like) pattern and those that invade with a broad, pushing front (verrucous carcinoma). In some studies, infiltrating invasion is associated with a higher frequency of regional lymph node metastasis and should be noted in the report.12 G. Lymphatic/Blood Vessel Invasion Vascular space invasion by squamous cell carcinoma has been associated with a poorer prognosis, including a risk factor for regional lymph node metastasis, and should be noted in the report.13-15 H. Pathologic Stage Classification The TNM staging system of the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) for carcinoma of the vulva is recommended and is shown below.2,16 Comparison with FIGO staging is also shown.17-19 According to AJCC/UICC convention, the designation T refers to a primary tumor that has not been previously treated. The symbol p refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible. Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (eg, when technically infeasible) and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer. TNM Descriptors For identification of special cases of TNM or pTNM classifications, the m suffix and y, r, and a prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis. The m suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM. The y prefix indicates those cases in which classification is performed during or after initial multimodality therapy. The cTNM or pTNM category is identified by a y prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The y categorization is not an estimate of tumor before multimodality therapy. The r prefix indicates a recurrent tumor when staged after a disease-free interval and is identified by the r prefix: rTNM. The a prefix designates the stage determined at autopsy: aTNM. Additional Descriptors Residual Tumor (R) The absence or presence of residual tumor after treatment. In some cases treated with surgery and/or neoadjuvant therapy there will be residual tumor at the primary site after treatment because of incomplete resection or local and regional disease that extends beyond the limit of ability of resection. RX Presence of residual tumor cannot be assessed R0 No residual tumor R1 Microscopic residual tumor R2 Macroscopic residual tumor For the surgeon, the R classification may be useful to indicate the known or assumed status of the completeness of a surgical excision. For the pathologist, the R classification is relevant to the status of the margins of a surgical resection specimen. That is, tumor involving the resection margin on pathologic examination may be assumed to correspond to residual tumor in the patient and may be classified as macroscopic or microscopic according to the findings at the specimen margin(s). T Category Considerations Lymphovascular Invasion Lymphovascular invasion (LVI) indicates whether microscopic lymphovascular invasion is identified. LVI includes lymphatic invasion, vascular invasion, or lymphovascular invasion. According to AJCC/UICC convention, LVI does not affect the T category indicating local extent of tumor unless specifically included in the definition of a T category. N Category Considerations Isolated tumor cells (ITCs) are single cells or small clusters of cells not more than 0.2 mm in greatest dimension. Lymph nodes or distant sites with ITCs found by either histologic examination (eg, immunohistochemical evaluation for cytokeratin) or nonmorphological techniques (eg, flow cytometry, DNA analysis, polymerase chain reaction [PCR] amplification of a specific tumor marker) should be so identified. There is currently no guidance in the literature as to how these patients should be coded; until more data are available, they should be coded as N0(i+) with a comment noting how the cells were identified. Sentinel Lymph Nodes The sentinel lymph node is the first node to receive drainage from a primary tumor. There may be more than 1 sentinel node for some tumors. If a sentinel node contains metastatic tumor, it indicates that other more distant nodes may also contain metastatic disease. If sentinel nodes are negative, other regional nodes are less likely to contain metastasis.1,14 Extranodal Extension/Nodal Replacement Both extranodal extension and the size of lymph node metastasis have been shown to reflect prognosis and should be noted in the report.2,14,20,21 TNM and FIGO Staging Systems for Vulvar Carcinoma Primary Tumor (T) TNM FIGO Categories Stages TX Primary tumor cannot be assessed T0 No evidence of primary tumor T1a IA Lesions 2 cm or less in size, confined to the vulva or perineum and with stromal invasion 1.0 mm or less*# T1b IB Lesions more than 2 cm in size or any size with stromal invasion more than 1.0 mm, confined to the vulva or perineum T2 II Tumor of any size with extension to adjacent perineal structures (lower/distal one-third urethra, lower/distal one-third vagina, anal involvement) T3 IVA Tumor of any size with extension to any of the following: upper/proximal two-thirds of urethra, upper/proximal two-thirds vagina, bladder mucosa, rectal mucosa, or fixed to pelvic bone *The depth of invasion is defined as the measurement of the tumor from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion. #The LAST definition of superficial invasive squamous cell carcinoma (SISCCA) conforms to AJCC T1a/FIGO 1A Regional Lymph Nodes (N) NX Regional lymph nodes cannot be assessed N0 No regional lymph node metastasis N1 1 or 2 regional lymph nodes with the following features N1a* IIIA 1 or 2 lymph node metastasis each less than 5 mm N1b IIIA 1 lymph node metastasis 5 mm or greater N2 IIIB Regional lymph nodes metastasis with the following features N2a* IIIB 3 or more lymph node metastases each less than 5 mm N2b IIIB 2 or more lymph node metastases 5 mm or greater N2c IIIC Lymph node metastasis with extracapsular spread N3 IVA Fixed or ulcerated regional lymph node metastasis *Includes micrometastasis, N1ami and N2ami and nodes with ITC. Only femoral and inguinal lymph nodes are considered regional nodes in vulvar cancers. An effort should be made to describe the site and laterality of lymph node metastases. Distant Metastasis (M) M0 No distant metastasis M1 IVB Distant metastasis [includes tumor involvement of pelvic lymph nodes (such as internal iliac/hypogastric, external iliac, and common iliac nodes)] I. Additional Pathologic Findings Presence of adjacent lesions such as lichen sclerosus has been shown to increase risk of recurrence and development of new primary tumors in patients with vulvar squamous cell carcinoma.22 Therefore, presence of such a finding is recommended. References 1. Rouzier R, Haddad B, Atallah D, Dubois P, Paniel BJ. Surgery for vulvar cancer. Clin Obstet Gynecol. 2005;48:869-878. 2. Vulva. in: Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017. 3. Tavassoli FA, Devilee P, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003. 4. Yoder BJ, Rufforny I, Massoll NA, Wilkinson EJ. Stage 1A vulvar squamous cell carcinoma: an analysis of tumor invasive characteristics and risk. Am J Surg Pathol. 2008;32:765-772. 5. McCluggage WG. Recent developments in vulvovaginal pathology. Histopathology. 2009;54:156-173. 6. Hart WR. Vulvar intraepithelial neoplasia: historical aspects and current status. Int J Gynecol Pathol. 2001;20:16-30. 7. Chiesa-Vottero A, Dvoretsky PM, and Hart WR. Histopathologic study of thin vulvar squamous carcinomas and associated cutaneous lesions. Am J Surg Pathol. 2006;30:310-318. 9. Kurman RJ, Norris HJ, Wilkinson EJ. Atlas of Tumor Pathology: Tumors of the Cervix, Vagina, and Vulva. 3rd Series. Fascicle 4. Washington, DC: Armed Forces Institute of Pathology; 1992. 10. Kurman RJ, Carcangiu ML, Harrington CS, Young RH, eds. WHO Classification of Tumors of the Female Reproductive Organs. Geneva, Switzerland: WHO Press; 2014:307. World Health Organization Classification of Tumors. 4th edition. 11. Darragh TM, Colgan TJ, Cox JT, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. 2012;136(10):1266-1297. 12. Drew PA, Al-Abbadi MA, Orlando CA, Hendricks JB, Kubilis PS, Wilkinson EJ. Prognostic factors in carcinoma of the vulva: a clinicopathologic and DNA flow cytometric study. Int J Gynecol Pathol. 1996;15:235-241. 13. Chan JK, Sugiyama V, Pham H, et al. Margin distance and other clinico-pathologic prognostic factors in vulvar carcinoma: a multivariate analysis. Gynecol Oncol. 2007;104:636-641. 14. Raspagliesi F, Hanozet F, Ditto A, et al. Clinical and pathologic prognostic factors in squamous cell carcinoma of the vulva. Gynecol Oncol. 2006;102:333-337. 15. Hauspy J, Beiner M, Harley I, et al. Sentinel lymph node in vulvar cancer. Cancer. 2007;110:1015-1022. 16. Brierley JD, Gospodarowicz M, Wittekind Ch, eds. TNM Classification of Malignant Tumors. 8th ed. Oxford, UK: Wiley; 2016. 17. Pecorelli S, Denny L, Ngan H et al. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Obstet. 2009;105:103-104. 17. Hacker N. Revised FIGO staging for carcinoma of the vulva. Int J Gynecol Obstet. 2009;105:105-106. 18. Oncology FCoG. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. International J Gynaecol Obstet. 2014;125:97-98. 19. Paladini D, Cross P, Lopes A, Monaghan JM. Prognostic significance of lymph node variables in squamous cell carcinoma of the vulva. Cancer. 1994;74:2491-2494. 20. van der Velden J, van Lindert AC, Lammes FB, et al. Extracapsular growth of lymph node metastases in squamous cell carcinoma of the vulva: the impact on recurrence and survival. Cancer *+.89<=E[\]fgklnorsǺǙǒ{sbTbh^PJ^JaJnH tH  h@$ h^PJ^JaJnH tH hwPJ^JhAhAH*PJ^JhAhAPJ^J hAhAhU]PJ^J hU]^JhAhA^JhACJ^JaJhAhACJ^JaJhAhA5PJ^JhAhA5PJtHhChA hgBhAh hgBh: hgBhC \]tq$ h$@&IfgdAbkd$$Ifl0$L  t644 lapyt^$ h$@&IfgdU]gdAgdrc m y $IfgdA $ h@&gdAgdAJkdl$$Ifl$V% t644 lap yt^5 c y X Y    ? @ T U V x | ø𨤨|q|q|h_\5KHPJ^JhAhA5KHPJ^JhAhAB*PJ^JphhAhAPJ^Jhw h$Gh$Gh5PJ^JhAhAPJ^JhNhAhA5PJ^JhAhA5PJ^J hAhA5B*PJ^JphhAhA^J hAhA*y z g^U $Ifgdi $IfgdAkd$$Ifl0@ $@   t0$644 lalpytGG xx $IfgdA}kd$$Ifl0@ $@  t0$644 lalytGG g^^ $IfgdAkd$$Ifl0@ $@   t0$644 lalpytGG |pg $IfgdA $ h@&gdAgdA}kd$$Ifl0@ $@  t0$644 lalytGG ~ $IfgdAwkd^$$Ifl$$  t 0$644 lalp ytGG @ A "jkdu$$Ifl$$ t0$644 lalytGG $Ifgdwjkd$$Ifl$$ t0$644 lalytGGA U V W gdAjkd$$Ifl$$ t0$644 lalytGG $IfgdA      G H I J R j k o p q      ! ǾhkDdh< hAhXhXhw hAhAhAhA5KH^JhAhA^J hAh[&hAh[&PJ^Jh[& hI5h[&h$Gh_\ hAh_\hAh_\5PJ^J8 | $IfgdAzkdq$$Ifl$$  t 0$644 lalp ytr   jkd$$Ifl$$ t0$644 lalytr $IfgdAjkd$$Ifl$$ t0$644 lalytr H I J R ! " w }vojgdgS(gdA<gd/ gdAgdAjkd $$Ifl$$ t0$644 lalytr $IfgdA ! " w OPjpѿќ|m|e|mYH9hAhAB*PJ^Jph hAhA>*B*PJ^JphhAhAPJ]^Jh[&PJ^JhAhAB*PJ^JphhAhAPJ^JhAhA5KH^JhAhA^JhAhACJKH^JaJ'hAhA6CJKH^JaJnH tH #hAhA6CJ^JaJnH tH 'hAhA6CJKH^JaJnH tH hAhAKH^JnH tH h[&KH^JnH tH  PV).[lRSĸti]i]i]i]T]GhAhgSKHPJ^Jh?5PJ]^JhgShgSPJ]^JhgShgSPJ^Jh7jB*KHPJ^Jph!hgShgSB*KHPJ^JphhgShgSKH^JhgShgS5KH\^JhgSB*PJ^JphhAB*PJ^JphhAhAB*PJ^Jph hAhA>*B*PJ^JphhAhAB*PJ^JphhwB*PJ^Jph?$"RRS$ h$@&If]gdZ3F gdA & F gdgSm$ & F ^gdgSm$gdgSgdA & F ^gdA & F ^gdAm$SaŶŭzpib[WNhBbh7j^Jh7j hBbh7j h7j5^J h7j5^Jhjh7j5^J h%5^J hU]5^J h,5^JhgS5CJ^JhAhA5CJ^Jhj5CJ^JhAhA^JhAhACJPJ^JaJ hAhA"hAhA56CJPJ^JaJhAhZ3F5PJ^JhZ3F5PJ^JhAhA5PJ^Jc^M@ ^`gdU]$<&dPgdAgdACkd$$Ifl% & t &644 laytGG$ h<$@&If]gd/Ckd$$Ifl% & t &644 laytGGbcd(?Ul gdq[gdq[  !gdq[gdq[gdq[gd7jab}  "#35GIYZpq}~&OYwy?Yi h7^Jh@h7^J h; ^JhJ`h7^JhI4hgBhC5 hgBhh<h( hgBhq hgBhk_hk_hChU hUhC hgBh(h% hgBh: hgBhChF Ph7j5^J3 #2FZq~5xy;e$gdwgd7$1$gd($gdq[gdq[gdq[i ();A  # $ C D !_!`!"F"G"O"X"a"b"i"{""""""""""" # #񼵮y hg 5PJ hgBhg hd;^J h(^J hw^J h u^JhJ`h[c^J h[c^J hgBhs hgBhC hgBh#hh^JhJ`hgK^JhgKhJ`h>x^Jh>xh7 hh7hJ`h7^J h7^J.)Ah $ D a } 6!_!`!q!!!!! 8gdq[gdq[gd` Zgd7gd7$gdw!"3"F"G"b"""""" # #D##### gd:p gd[c <<gd/ $ h@&gd[cgdg gdg  8gd[cgd[cgd[c 8gdq[ 8gds  !8gdq[ ### #,#D#d#k#####1$f$$$$$$$$$$ %%%$%%%J%q%s%%%%%%%%&&&*&H&I&¾¶­|xthCht h(^J hAr^Jhgz hyft^JhgShAr>*hArh]hyftH* hgBhChJ`h[c^Jh(hg h:ph[ch'h[cB*phh[cB*phh[c6CJaJh&h[c6CJaJ h[c5PJhh[c5PJ+## $($1$D$V$f$$$$$$%K%p%%% &I&u&&&F'gdq[$gdq[gdq[ 8gd[c gd[c gdg  gd:pI&M&[&t&u&y&&&&&&&&&&&&/'9'>'E'F'G'I'Q'Y'z'{''''''''''''( (/(V(X(d(|((((ƿƿƱƱ~z~hH hAr^J hgBhAr hyft^Jhs~hAr>* hAr>*hr+mH sH hArhArmH sH  hgBhr+ hhz hgBhzhArmH sH hr+h_&hX | hgBhxhxhzhhArhnh=[ hShz0F'{'''''0(U((((.)Z)))+*`*~**W+X+y++++gdq[gdq[<gdyft/gdArgdAr$gdAr/gdr+gdr+/gdq[((((((())-).)2)@)Y)Z)^)k)n)o)))))),*.*6*>*_*`********************µh"C6CJKH^JaJh^56CJKH^JaJhyft6CJKH^JaJho6CJKH^JaJhY6CJKH^JaJhZDhyftH*^JhArhArmH sH  hhArhArmH sH hn hShArhthAr hgBhAr0*****++*+,+T+V+W+X+]+_++++++,%,9,,廮~slhld]lhQH*KHPJaJhEkh6>*KHPJaJ#hEkh6>*B*PJaJphh6>*B*PJaJphhhhsh/$h:=hA6B*CJ^JaJph'h:=hA6B*CJ\^JaJph.//#/d/m////////////00!090a0g0i0u0000111#1H1ض{r{ibi^Zhh%P hgBhAhgBhAKHhQhAKH hAKHhz[~hAKH hA>*KHhQhA>*KHhLhA>*h{hhm`g hLhA(hrhA6B*CJKH^JaJphhA6CJKH^JaJh'hA6CJKH^JaJh/C6CJKH^JaJhA hmhA /00a0u000011H11111A2B22$gdq[ ^`gdgd7j^gd ^`gd/C7$8$gd 8^8`gdA`gd7j$8^8`gdA$8^8`gd7jH1s1y1111111111$2*2A2B2N2Q2a2g2o2q2y22233374i4t4|i_VMhgBh[KHhgBhCKHh;yhC>*KH%h h B*CJPJ^JaJph+h h 6B*CJPJ]^JaJphh EhsH*hshq[ hgBhC h^Jh@nh^Jhhhhh#hB*PJ^JphhLVhB*PJ^JphhyQh^J h^J h/C^Jh@nh/C^J23374W4i4444445566785xgdwl n^`ngdq[$n^`ngdq[$n^`ngdq[$$n^`ngdq[$gdq[$gdq[gdq[$gdw$gdq[<gd/t44444555'5S5W5Z5d5}555555555556g6l6s6t66667 777-77787?7W7Z7777ǿǿǿǵ𓏓}#h Ehr+CJH*OJQJ^JaJh h@ohRh,hs=hnhCH* h8hH* hr+H*hgBh Eh Eh EnH tH h$h EnH tH  hgBh Eh Eh EH* h Eh Eh EhC hgBhChgBhCKH,778888'9)90919D9E9U9[9^9f9h9i9999999999Ź}vrng]P]JD hU6^J hF^Jhq[hF56>*KHhq[hF5>* hq[hr+hCh[ h;yhC hgBhChnh#6CJ^JaJhn6CJ^JaJhnh=P06CJ^JaJhnh(6CJ^JaJhnh(6CJaJhw6CJH*aJh8hh8h6CJH*aJ#h8hh E6CJOJQJ^JaJhwCJH*OJQJ^JaJ8h9i999999999:<::<<<r>>j??&@@@gd7j n^`ngdq[gdq[gdq[gdq[$gdq[xgdw9999;:<:@:G:H:::<< <<<&<(<.<0<6<<<><t<<<<<<<<<<<<== > >>n>p>r>>>>>>>??Z?\?^?f?h?j??????%@˾ۺ˳˳۫ۺŧ˾ۺŧ˝ۺ˫ۺŧ˾ۺۺhgBh({8h({8h3E hJ0h({8H* hgBh@ohq[ h({8h({8 h3E ^Jh({8hRh hC hgBhChq[hF56>*hq[hF56>*KH hF^J>%@&@'@(@@@@@@@@2A3A4AmAnAoApAqAAAAAAAAAAAAAABB Bÿʷ㕉{snfafafs]hP h >*h>&h>&>* h>&>*hyh&Q~>* h;yh&Q~ hgBh7?hWhj{6CJaJhWhunI6CJaJhWhj{6CJH*aJhj{hj{H*hj{h ;h: h: h: hgBhC h7jKHhJ0h({86CJaJhw6CJH*aJhJ0h({86CJH*aJhC"@5AnAAABRBHC!DDgEFFFfGG`HI^IIIJ$gdq[xgdw$8^8`gdwgdx@8x^8`gdw 8^8`gdq[ BBBBBBBRB\B`BbBdBfBvBxB CCDCFCHCRCVCXCZC\ClCnCCCCD D!D&D(D)D*D+DDDDDDDDDDgElEpEqErEsEFF FF$F&F2F:FtFvFFFFFFFFFF G GXGZGfGh@oh#hWhRhx@hWH* h6EH*hWhWo(h@h:hP hWhWhthx@LfGpGxGzG|G~GGGGGGGGGGH'H6H@H`HeHhHiHjHkHHH I II$I'I(I)I*I]I^I_I`IfIIIIIIIIIIIIĸhmHh#6CJ^JaJhW@O6CJ^JaJhmHh6E6CJ^JaJhmHh(6CJ^JaJhmHh(6CJaJhw6CJH*aJhmHh6E6CJH*aJh&Q~hh@oh#hx@h@ hWhWht2IIIII JJJJJJ,J.JGJHJrJxJJJJJJJJJKK K K"KTKVKaKcKKKLL L"LLL,M-MSMTMMMMMÿ÷өӥӡәӎӎӎӎӄhgBhCH*aJhgBhCCJaJhgBhCH*h@ohUhgBhC5CJhEZhX |h6EhRhhCh27h_ hgBhC hgBh: hgBhWhmHh(6CJaJh(6CJ^JaJ1J,JHJJJ K KSKTKaKbKcKuKvKKKKfLLL-MTM & Fgd gdq[gdq[gdq[gdq[$gdq[ $$ !`'gdr $$ !gdq[$$gdq[TMMMMUOVOoOO+PPPPQQ+Q"R$RXRWWWW$<<$Ifgdq[&dgdq[ & & Fdgd &d^`gdq[gdq[gdq[ & Fgd MMMM`NaNcNfNUO|PPPQQQ*Q+QjQkQRRR R"R$RVRXRRSSSSSĽtldZhgBhCH*aJhgBhrH*hrhrH*hgBhC5H*aJ hb5hgBhGhG hm^Jhbhm hm5hgBhC5 *hgBhCh@o hgBh hgBhC h}hC h}hwhT>hCH*hRhCH* hUhChUhCH*hkLhCH* hkLhC SSTT^T_TTTU&UiUoUUUUUUUUU6VoVpVqVVV!W"WMWNWvWwWxWW X XX#X/XcXdXhXXXXXXYYYY/Y0YbYYYYYӺӮӮӮӮӮӮӮh.[c5CJaJhFCJaJhgBhCCJaJhgBhC5CJaJhgBhC5aJhgBh@oaJ h@oaJhgBhCaJh.[chmhgBhCH*aJhw hgBhC hgBhm9W X XXCXcX_kd$$IflF&C  t06    44 laytF$<<$Ifgdq[cXdXhXvXXn___$<<$Ifgdq[kd$$IflF&C  t06    44 laytFXXXXXn___$<<$Ifgdq[kdD $$IflF&C  t06    44 laytFXXY YYn___$<<$Ifgdq[kd $$IflF&C  t06    44 laytFYYY)Y/Yn___$<<$Ifgdq[kdp $$IflF&C  t06    44 laytF/Y0YbYYYn___$<<$Ifgdq[kd $$IflF&C  t06    44 laytFYYYYYYn_R_R $<$Ifgdq[$<<$Ifgdq[kd $$IflF&C  t06    44 laytFYYYYYYYYYYZZZ$ZZZZZZZ{[|[}[[[[[[[[[[[\\\\\D\N\S\\\׺||xtphRh-$hwhhCZhdPh3c h]dH*aJ hq[H*aJhgBhCH*aJhgBhCH*h;y hgBh\U hgBhChgBhCCJH*aJhgBhCaJh.[cCJaJhgBhCCJaJhbCJaJhgBhC5CJaJh@o5CJaJ*YYZ ZZn___$<<$Ifgdq[kd2 $$IflF&C  t06    44 laytFZZ$Z=ZtZZZn__R_R $<$Ifgdq[$<<$Ifgdq[kd $$IflF&C  t06    44 laytFZZZZZ[[[[\nga\WW\WRgdq[gdq[gdq[$gdq[<gdq[kd^ $$IflF&C  t06    44 laytF \M\\\\\\+]9]J]T][]f]h]y]]]]]^0^M^]^p^^^^`gd $gdq[gdq[gdq[\\\\\\\\(]*]+]h]r]s]x]y]]]]M^N^\^^^^^^^^^^^^____6_7_;_M__ž嫤~voh hgBh\U hgBhrhgShr>* hgBhdPhdPh hdP>* hw>* h-$h/a h/ahX h/ahb!hXhu?hr h5 hC h5 h/ahw hGchCh h0H* h5H*h0hC hgBhCh hWa>*h-$hGhWa(^^^^___6_7_M_``aaaGcHclc0d1dUdBeCehhgdGgdq[gdr`gdq[`gd ^gd gdq[_A`B`d`g```/a0aratauavazaaaaaaa[b\bDcFcGcHcLc*d+d,d-d.d/d0d1d3d5dDdTdݥݡݜݥݔNJtpga h(^JhJ`h(^Jhq[hgBhC0JOJQJaJ h5H*aJhgBh5H*aJhgBh5H* h5H*hW hgBh\Uh hCaJ h0aJ hFaJ hGaJhgBhCH*aJhgBhCH*h@o hgBhCh hwaJhgBhGH*hG hgBhG&Td e eeeeee?eAeBe&j'jk!kkklmymmooGoIo\o^ozo|oqqqqqqqqXrYrs/su~uh8h(^JhgSh(5^JtHhgBh(5>* h(5>*hgSh(5^Jh(hgBh(@ hgBh(>* hgBh(hC hq[H* h5H* hgBh5 h5H*aJhgBh5H*aJhgBhCH*aJhgBhCH* hgBhC*h&j'j7jkkkkllxmymmmmmmooGo\ozoooqqgd( $ !gd(gd( hgd(gdq[qqqss/suuuwwwDwwww x xx'x:x$ pp^p`gdq[$gdq[gdq[gdq[gd( 7$8$H$gd( `^``gd( hgd(gd(uuvvwwwwwDw^wawwwwwwwwww xx'x:xxxxxxxxxxxxķčwofZh hCH*^J aJ hWaH*^J aJ hX^J aJ hgBhC^J aJhgBhC^J aJ hgBhC^J aJ hgBhCaJhgBhC>*]aJhgBhC]aJhgBhC5\]aJ hgBhC h h( h(H*aJhgBh(H*aJhgBh(H*h( hgBh(hgSh(5>*#:x`xxxry zzz{{{{|<|c||| }$a$gdq[gdq[ gdq[ pp^p`gdq[$ pp^p`gdq[ pp7$8$H$^p`gdq[ pp^p`gdq[xyySyUyqyyyyyyy\zfzzzzzzzz{{{{{{{{{{{{{{{{{{||5|ùװ|xkghWhgBhC5\]aJhhG hX^J hW@O^J h6E^J h=P0^J hhG^J hc^Jh hWaH*^J hWa^JhhGhhG^JhX6H*]aJhgBhC6]aJhW^J aJ hgBhChgBhC^J aJ hgBhC5^J aJ hgBhC^J aJ (5|b|c|h|i|j|m|n|o||||||||||||||||T}U}[}\}]}}}}9~:~W~X~a~b~c~e~i~w~x~y~~()*AcjvӸӭ楩枩hgBhC5\]aJhgBh{56\]aJ hgBh+hRhWahgBh+^J aJ h+^J aJ hgBhW^J aJ hW^J aJ hgBhC^J aJ h,hU@h+ hgBhWhWhC hgBhC3 }Q}}}~:~y~z~)*A\ $>^`>gdq[gdq[gdq[gd $$a$gdq[$a$gdq[ pp^p`gd  pp^p`gdq[vLMӀՀ lɁ ,`bcpŃӃ<P5xz|̅{qhwhCH*^J-hwhh!6B*^JfHphq *hwhh!B*^JfHphq hw^Jhwhh!^JhwhC6^JhwhC^J hq[hq[h U h5H*h7=h5h h55hgBhC^J aJ hgBhChWa+ ̂a̅҈-C,, >^`>gd  >^`>gd  B^`Bgd  >^`>gdq[ B^`Bgdw̅Fp܆݆·҈Ԉiv -/|͊nڻڻڻڻhwh 6]^JhodQh;h^J hw6h 9hw6 h 9hwhwhwhC6^JhwhC^Jhwh56^Jhwh55\^Jhwh5^Jhwh H*^Jhwh 6^Jhwh ^J0(.CE,,,C,T,,,,,,,,,,,,,,,-&-'-(-)-/-0-1-ƻƯƧƚ{qkq`hI=0JmHnHu hI=0JjhI=0JUh:hI=CJaJh%hI=hFjhFUhwh^CJ^JaJhw0J3^Jhwh50J36^Jhwhw0J3^Jhwh50J3^Jh/0J3^JUhwhC6^JhwhC^Jhwh ^Jhwh8^J%. 1995;75:2885-2890. 22. Yap JK, Fox R, Leonard S, et al. Adjacent lichen sclerosis predicts local recurrence and second field tumour in women with vulvar squamous cell carcinoma. Gynecol Oncol. 2016;142(3):420-426.     Vulva Gynecologic CAP Approved Gynecologic Vulva 4.1.0.0 PAGE 2 PAGE 2  2018 College of American Pathologists (CAP). All rights reserved. For Terms of Use please visit  HYPERLINK "http://www.cap.org/cancerprotocols" www.cap.org/cancerprotocols. CAP Approved Gynecologic Vulva 4.1.0.0 PAGE 6 * Data elements with asterisks are not required for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen. PAGE 7 + Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management. Vulva Gynecologic For Information Only Background Documentation Gynecologic Vulva 4.1.0.0 PAGE 20 PAGE 13 ,,,,,,,,,,,,, - -'-(-3-4-5-@-A-B-D-E-%gdC hh]h`h &`#$gdC % !`'gd:%1-2-3-5-6-<-=->-?-@-B-C-D-E-F-K-L------------뷪rr_rQJFh[ h[&hNh[&B*CJKHaJph$h[&h[&>*B*CJKHaJph*jh[&h[&B*CJKHUaJph!h[&h[&B*CJKHaJph!h[&h[&B* CJKHaJphI}hU]5CJKH^JaJh[&h[&5CJKH^JaJhhACJ0aJ0j hUmHnHuhY0JmHnHuhI= hI=0JjhI=0JUE-F----#.$././//c0d0000000% E^`E hL]h^`LgdN&`#$$ L^`La$&`#$ % !`'gd7j 1$7$8$H$gdr 1$7$8$H$gd[&-.".#.$.%.+.,.-.../.@.N.S._./////////////b0c000000000000000ܴzzoh UhI=CJaJh7jhU]CJ^JaJh7jh wCJ^JaJh7jhI=CJ^JaJh:hI=CJaJhNCJaJhnhNCJaJhY0JmHnHu hI=56hI=0JmHnHu hI=0JjhI=0JUh:hI=5CJaJh%hI=+0000000 >^`>gdq[ hL]h^`L&`#$00000000000hwh^CJ^JaJhFhY0JmHnHu hI=0JjhI=0JUhI= C 0P&P:p/ =!8"8#$% Dp@P&P:p:/ =!8"8#$% Dp@P&P:p:/ =!8"8#$% Dpj$$If!vh#vL#v :V l t65L5 pyt^R$$If!vh#vV%:V l t65V%p yt^$$Ifl!vh#v@ #v:V l  t0$65@ 5alpytGG$$Ifl!vh#v@ #v:V l t0$65@ 5alytGG$$Ifl!vh#v@ #v:V l  t0$65@ 5alpytGG$$Ifl!vh#v@ #v:V l t0$65@ 5alytGG$$Ifl!vh#v$:V l  t 0$65$alp ytGG|$$Ifl!vh#v$:V l t0$65$alytGG|$$Ifl!vh#v$:V l t0$65$alytGG|$$Ifl!vh#v$:V l t0$65$alytGG$$Ifl!vh#v$:V l  t 0$65$alp ytr}$$Ifl!vh#v$:V l t0$65$alytr}$$Ifl!vh#v$:V l t0$65$alytr}$$Ifl!vh#v$:V l t0$65$alytrD$$If!vh#v &:V l t &65 &ytGGD$$If!vh#v &:V l t &65 &ytGG$$If!vh#v#vC #v:V l t0655C 5ytF$$If!vh#v#vC #v:V l t0655C 5ytF$$If!vh#v#vC #v:V l t0655C 5ytF$$If!vh#v#vC #v:V l t0655C 5ytF$$If!vh#v#vC #v:V l t0655C 5ytF$$If!vh#v#vC #v:V l t0655C 5ytF$$If!vh#v#vC #v:V l t0655C 5ytF$$If!vh#v#vC #v:V l t0655C 5ytF$$If!vh#v#vC #v:V l t0655C 5ytF$$If!vh#v#vC #v:V l t0655C 5ytFDd&X  C 4ACAP_logo_cmykb2tlS4Jێ8$n2tlS4JێPNG  IHDRCLgAMABO pHYs.#.#x?v$tEXtSoftwareQuickTime 7.7.3 (Mac OS X)_7StIME# IDATx]`Eݻ$ MA EA(|YPPbS "*tHzMPͼdnr% x?7;7a4*N} *p B_8 b*i'!CwraمGEqtTJwV*QPGAliD){:{V58TîC-*OaFaF;"!6vaPkJY"ͪE&mfՔҌ($5\ƸuáDh6+ ܰzUzWr# ,M ߚ nuLceDaFaFJX;饓d"('TI}BjjYlْѸq^ziӦ(ց4ToS||)N( 504EW$/Ԫ=F<, \Й^0M6, vәf߽3BN UMqj"ia s0#0#KM 0TeLGmF_5b؈yʔ)? }yO<9&&Eo[Ŋ CZJh:Rtzަ)mB:Uшj3 5hYwbTBrS.8`1s6rqo #0#0bA雂'-&NjdkΜrFd L[hqfo\`ATT lN(Ŧa;3TA bMg:ev6V@16oLk LZ7lY/[٢}[U.O=gLhUQXFaFaq(KY'gznݳ33y{lN믿&NBi/2Rrt`:e*@s~?a~";weFa0AnSPN$k\꾭 nm$$ߕ?9'Q4cNa#0#0¸$PzĚNhA*33#JJLRr":ujvv6)j,^|'hrkUdyCWM+ġ2u ۨ j5kU9MaPi>ETZ&M0 7 &0#0#KF*[m={ΦS2k V2se+_^RWs{u^L5N%%G3tfh*93l:_ު haѺv‘<+q57%%#tKJ)܊U,C4HU-(FaFaFԈ53DV]N64Cf͊Όn DFAW9Ӊ@IUZgff<Y` %4u@t"UVkLF8@ UrSnPeQjPa租g̎\+U/7aFaFaFtA UtA"/JF/cʙZqUjUB@mvHHB9U6uç2?5E1l6zفv i`z jֲ1F v'}/ܿ1!*c*a^FaFaq4Lrg,f}Vv2TK.ZW,uIϞ=9vt8S3ʸUt9z DfP]qEUc؍1s꺽\DC+z 5[afJjÙ0#0#0.kRf<~E&}^#ޘDPĻ ];vn:׷nݚ}x8G{CHbh[jTEڦ+P#umV&EvK@[;8qɫlȫ$6V`D7tU:=0#0#2R#NKv9#69unyD Funݺ߿Wع60`+$K,v&CLFlt r:WS*6,꿩'OZ9s :=yيM8~0cv9jV240#0#0¸DPzkAUц s.tWgh| ߟ]~xwhR#ƱAif#)6DW> S ΌItpcz:nZ(MGnmM1r`GUp!oNۘ&N]rڱ=-<ÜFaFaƥ  3jkt?cXVDj8_zlSÓwz||AA+_ v .Hy!2KRQHA#ݏ^bͦ T( #MB!Ule (Јu!dW sr BJkώ3T n8}q*nA Jd/ᙬPCWX$Zb:i"@YCHG ?XJ}L3O7e*e!*shw]WPZ,e|AH[q4mNl8UnӨ)v`8?^^Ӊ;鳃  ,hLK9z(H5!K-襇Pz ڗ N$E]dZ\:QU$؅+$, φםX%VSe*2X !)-x]۔֯>RT ^eKxO׋u5s_:'3k}f<q` pƏ[Nz}oC35VrPz&}jC0IxkoG)u(K X7&mY@.3[Kf$DM0{ [p*$t^A|ꛝ[ bqgG%;tðC%M6Bb6 BE\Yd[aNy~*Cgpa=ʔev]^B񵾏PzJa~{!\JH*RWz}:Xn,1I* NHLAN<߼ys)knu繁LUl3׉MU 3 רN[VdMi Ue(b;رcGjѢEx"*ׯ__ٳUjjjffUVW^f:vxuƖ<׮]{Ç={@]C5klҤIVnFhA ဘ[l٠A .EJt7C:n޼ѣD111 3\.@e˖mڴi޽ٳ*VX\u6jkԩW\! _rPABʕq^Jl vѢEƍO8׸qn_>VZ!gϞ0\tm̙v=D"A߿?D /ѣGҐӧ%$$|W|CAAҥKg#wax[:tKJ*Uu;Lsϟa6ڵ+w,36-[s}]vh0Y`kzW U~OZj!{ꩧa^xqD3x@ˇB2nb0pqa=5^u[\:Zkt3"^F~D򚝻Vef;& dPvCsOΝu_ E|3wQ§%@mmۖ0>P^^ `|IMVĢ뮻Ν ˪@D$3fz Ek~a*V'11 #c2z-1SJS&7g}VJ—6 PwyLn20K3ԩS_)kD D҂YzH01tP.w}`1p&+/5۷S޽iJÃ+WQ  âGXΨQĘ_|E?r\fO<kN =iӦ[?O}Ȑ!o:y Ɯ ^W_}uZ TCxq7fgg}(ꚴv\~ku;Z#^Ɲ71ݬMzXoߵz5w8{p2Bh맭?9 "ֳם 6t RqȬy |nYÇWn1,0c-Zp;ym7n U,RF:~ Ӈ~XV-B^zZWhBR~m{wb^n ?uW]uo<RDDzwCh~^T.][e0K55jXn]i QR%. ̸KkR]S{Rܹ*Fl٫ G,VBb{k.*u־6E+@0hXO^0)((($X\ƞ?^ ?l0YM?#7b$!.RBp 7^|:x23f[N#|M|N;*&gGr(&l;$sqVLN'.Q|T Z1tE'^{ߔܤZcF'āɟx=Cԯv]gR(~9r{6a6c1X#9h%A9sF,K;v(зo_ ެܒ}{IRR,D x-[B=y$d~]hxx{Ν۶m[V0^MO_DxE+_SPS a=1oFf; !$I.}'MԠANjUfQ" ;8Fİp‡~|jMIIyJT8_}UZZiӦe˖"!׷~)Z݁Իg5ҏ* F_#`=}A,?+B/FcQ!],\iHw 1@U稞8L3P~|ʠ0=GW|:?b'x#%dWl*"[ÙX5~gƍT"]իכosL8bFFb!-+ ۴ifa`r2qo>3sZ>[n:-s礬}  p㹝|b)nBIT>KT@-n ,ۏ5*77ךں%vb^9uWhW"Z0+XBNNc=ƵS\\\>}:V*:uꔨ.`ZՔtAOmO9v7|# ,X~Z q7+cˊEEK,@u O?4~۟|_~'qΝk6K7wݩS'n$ ig>(&7aX Jx&ͣe}$Ha͑0s&hj' k订+ U@67TXr lP,PevNYҙgx!3K3MiP@[౎Tcl!zS .l0.]ԭn~/\h… "ٻw/p2|&C HkӰaC %-Z_~ ӧegϞ5mh.W/p@wqP|^bVZiӦk._<4߶m۲e6l rP|ԧ~:p@Rt@Zݲ-D1h .f$$$Kŋ}ݙn{tbbb۵kפIի@< `ɒ%yᤰwwt5k4%@ 33 :xq$$O ֯`IIIWf!a_Ks[%C}xZjLQݺuT/\c͛a•?ߠa2Gf_~E&Я_?t[s:uꮻZbEN&DڼG' sS *GP|O F::p(p"!zH 4 :<~g*D%'A"{^x;PvUf#a)ڠsӦMă ~Х?#M4iΜ9gSNR. an'N[vELZR< D\\sM߾} mʔ)ǏGQam KPXMڗz3G5'xu~"1 ^1cƌ~{Jw}`̱5o޼gϞ#Fo裏y^0o6^Ib^H" ߄< VP@(?cW^ɏ icHw!Ck]!ų|r|.q ME@#XWTɫg„ Ehߎ;²ܗD 1*u.< ~.a#Њ?l6)0l"ǕڵkawߡXt)LӧO-T5]ļCu-)ZMW |r/m bs5ˇwP(blT r5զz^2 Jt#(n Tـhe T:vtflʳWdFA' Uɦ"0ћ"3..NZPfM"9,.m6%.}pCY0Š%`{1{l15Ѭ, i --[oHZnjժ?eSm:uǎ{Eޜ/p;< @/I.d(xYc5>FLpE# i˖-?jMUFC=tرc+V( 1e=_6V-$7o&BB濊Y t؇zT Z&¤+iӦ>}:P>$xWg̘1bҒ CO4yQiΓ׆  IIIo Ku*j1LxT#NI uŋ{2h"p#/}>Qb"pЁۋ5THfRm[ѐ ?ԦDQ݌TA-=؃ Ȗp q*1(v`THv骸JJz*U\~R~tkV)] '$$###[sKx^dɒ'BwlN&M^'n׮Yk]wݵ}v1 hQGްa6`ǥ)_ȑ#ab>of3 )Xӏ6:$YbfPw}7jhʕ+JO\#QQQ@!Ν; )A.Rl۶ /R1qᅸhS IDATɁdtSRR&M$ bcn{P UVZ\FJhbƍև xz+ݻ͛ce۶m.\XbEe{ץ=@3Gf ^zI=Dѐbg`~ 33{{;a5j=8֭hѢmSPY&ap@˖-`i$%%xVB~ O0ba1*;[uPʊFUW8K+hN R+ 09eP2˘\{0{`ǖ/_Sɠ'Э5fp!j`&́#h>Di@LM3ҷFN4]AyĦln8Ɔ%;l:_#YsnFHڵU]36%кJm gݬiFlluRQ#iWeWS]!xع d|-Hqrȕ^\-[[=#K e\떜 c5k@SZ` zžjLpPΨyq~K={6[fZZ}a ܖK7z PnSʕ+׬YC߆wpտTAEcؐMF<55ai֖o5))))3?"íZk,SNZdRڿPիd +Ou7n &%KlذQF$H=uT R O8G:uĮ]h84b]jU6t"pT f"Dg^^ڰ1Zۉ UQ5V$ 5!Mh]E^ZbĺQ`k&0Uܸ~"f qOGVzgc܃uo۔XF20Cm6ۯ㏋ 7L̰d$>xꪫayR^z%IQZ5X0u'x 75,X "`֭/bwA0ZNA% sog}k/>裞={ q1N:'83 WNK ]Eؓa&OO(<'69qO&v*3n8 jl FF #ԬYsҥ+V=z U}v09(::PUƉ vC-PCP @^Y;nol;^Mj_fMԌD\V;!F||b5jP U,,6̙y{vf\Ns~WC7I&ٳ'x^>}.)"eîy2xK?M2nݺ~{qaΛ7}GyuAn̙ވ:bRZ5}& Ç [E޽~ôTї@.IHhKĦoJfAg}VwE0NN:,de˖DϿ&$$cX^N3,gHٳ+oڴiCA$Uߑhxp">'C?<Θ1NL,At]R=N5j6kw^~U붶Zo<(p\;c֋|ՋQ 9=ԁݦǙ4n9K|VR3}b~ڝo%E`۾z!~7Pyo uZR&K~ӦMb,::=sϩ&vPx9O*;ΆųJL|Ց`b]:tc. ӦMОgZ,t(s TL_m߾=&&Fŋ+-[H(gsoUn@6@`j6yڽWiJ%5I jVEWkFtK!:DQm̢T\ )ęE\e"Gjg FTL A̞;թۯRzc\*ٳg5f*22Rphݺub}7TzkEKr/.;qDq"EaڵڏBXץUbˁsjj8UY.es$\2uJkTҎ1T`]9%$$xڻo`AӴ yșFy!lܸ;>At%TE1-Z;@~tONJƚC$Ӥ(D85&U BGWS/W6\\1U.Q|Y <Ά:a登 *ι˕Vm;ñ.Cz#h"7 ckΜŎ3gJ K(w_4ir}VJ F[` NWXqKr/F>5W}PKԧ(W]tiݺ5Ě;aW^JkL?W"ݑ/LQI"99xE!2GΝ۷oo Ɖ"(*U׏ݻ7kL|dp= 6LK^zFFsU#*d}k]gg%L3l8TLŪт̗}:5FK"= 5J)А0kpMcruUndi^\_;|@ Λ7OFtE?sPYx%0H9hxp _"%Y+JLzܹIIIop!ϝ;Z!vRDspD 8t7B6~嗘aà*NyqVt&IR\RmFfV'c3oTRMQӔ[334f Hu/梆n;)Q `m U,$J1sN[-Zy7=E7-a;&[eM~R2LP[+@g0yna`"ܱcGq?~8̬0nՔ5@ih߱>' =â0A1שSGt k!KČΚ9>UJX.8)1cB{}Yܭ/ ,O>ϢE)'N3g*F-iCԹ̢k~asۡ0Giii'OW^A@ RreOӥ9_/,yT0?;x%gׯ9#]9T]u[8A\":tP&Qh ,%*F cǎ5)]ٲe)S$h} =i48١:Ҏ9iΰ37^;3UüB1惏}:R݅q g9` 9 j4%ڔ%)];)JD/_^<裢Da)L ?U{… ZT,x+&rA0b)(??afw{_y)zu+InO_+V{nE:|q'sQPBqunKR|WfJ b[;xAtMn'˼I@:rHH9BuȑR6oEpnc AYْB\gcOUuk[y~mڵ0ܽ3†2s%5E9gNR ձu˖-?y=gq47_(W3sggeek2"r$LhgfIH/`"W9q $=;lFFv^Ӫo-*y@:.J``F <5j r.==hsOKbVQXMe";%pЅHNNaʵneF!'OܦMG~~X[T+L=%ӡ0?[~ˆb.Ϛ5+NxVC1)Zt\jn$o~ڢ2\pubQveO\6`灔|h&6yC34Hs ;p@NAuf2,fΜ I s˗/dBVrڑ- n\LF7Y[};biwΝ;o޽W^0f<`Q[EAe0jBN=89(Mx2ӛ5|'sm'YޞcYzDK{|ּׁ%"5AAv۟Q,ҕE5ahSRsթJ l|t(DFFRХ%@TJ4"] !|a]'Ō/&r5NH Pӧ { V@m޼Y zMqq ”t5и @oO\s|8/@򏈈bꫯ֭[zN:N`HeP1"=E%Db$THW\!E2]xu7pϚy?ܹk~dka?X5Q@Z'@y!ð߁c' 4(PHj׫6`CԯNjSƸ*h0j. t SݏGuion0;4y;t%=*^^U^zm۶]w\RP.86䙣y^Z5os3|ҳ$;Tf[(ZSwn>~Mn#kdg:t? 3ؾNz)dāMb"E[dz-TXC٩]HK8}z|<kjy9w\#~EX fwJ@S~1߂#`UT )`a!چ Ξ=^zŊؽ{ -iY5رcoHԩ3~[ /]0q_Q+bܸq< AXCrIGDY]vc}'|뭷rrr0XC (L^z?UfP<ׯ֏H\uU~q=g_z>}ztttɴ@Q'<^~Лs[馛Zhc^&Lxgm6[+-KkfͦNz]w;ްa_5~;!Mi@.UNwQ}1nCM8ODw;b_A\eۨQxp'++Du5ބZW'%i dX5ؼ!ڴiTJUy2GEE0_~o(=z4ܽ{wщ/1`G) q#)*3b38\OG{a@D>:ҳ,|F5yӟ6Q'\0ӧJSѳɩMW&F8sbhr4]ԖʯkZ;cK6giNSnc1NQBX5fcL 55?0 rD51抚;t'en(iUVh+\l77oίA 65Q`u-[_K"@кuk+PbK Kڈ#7n, ^UVn'=fϞ;JI $.X`Νb?"|X̔)SΞ=kNK<0BJ6 yLO?MMM>_o6" w8@.׮]{W\ TǬ MXgD(vb*d816ʠN;Un9C5t6(w~WL ^s!2UGX|y$ zɋt+tn5jܹ(T+?`j5GPmfL5- >^k|뮻N @թ4~@4mUGv cؕoFp,0 t]% Xܼ:lz]O(j_i wOʅ)gscxMEȾ ~ZAɏ}^dɺuN,_ZױcNJjժ.샓ݻ82җJ+v@(oF p 6\29z(rԦM;yF`Tƍ')srr>|?cxCS.%>}f͚իWm@Vʕ+IgKRG\ Mի*ܴnt gh[3۵kdI&ԩ NQs?2@hLYuD6FhLDca`Ͽe]&ևnHUȆlJJD+ ./ +h(΅ZbܮH$n*UjLބ|G\^Ag".(f,hҢ]-Ɖr@ O{Oթ599` FF6i \& :b F"A#J PM0[ 2Dl6V^eğ}'AX[.DW\!ZPP'{O Qt.?LԂꡂ̲j+YPz+*H%EO۷otn nZF?{y? <[W_z0Z_Z]a #EvA9< 6l0ڼyf͚:IGԽzFQ^1<\LOP%'PԣGWiv |I똘Y-m9;3O3jGدMTSVJ*h۶mۂ n믿Cpi]QR]xiغ/>oiw{u[=Dtj͉4;ǭ&%%-s͛rrru2(:h^ja˝ګԨV3!>-#=FGW丄(.k wJcct i;ss54R*ݘHB>S]#$*DEjP/#'7-+@Ӣ"lcccʹ)[Mb@]kᖔlܸbŊ^bYhXk){}W]u{JRP!`£E⻴A0D6tKHU7xC|?N M ܦx0/+i?7& s0jժ$ )/ؠA?̟?/E{|75@#GΜ9ĉjx,t [O& {ɓRܵkԩS67o޷o3f x۴iS~}?JCzĿ$xŝcO>+?8ddΜ9ڵx0qy?ifhEI/47>cAݙEL`A4pQnA DW@U(t5Wk+4§J"oԙIVb~ЗLY<>Ca0u*B0pY!:ËoS^%?7x/O*U*n 7łjIQ.Y}I"<Ń LLL\ dLXz͚53')˼>S*KtE,X`c aJI wHl _ :u¥2k.SƄ B0j];vL E}b`X'<ӱ۷yxwů˗'iΔUVLHADϞ=,RO7q\Sv sF[f;V 5@ b,cβ ]uB[x!REskGTBQ z2s{Uq,GTB3uCuL4;6ba2/[ o̹Ze4ƶ`VZf?3gv3*W,Ç_{3 yb FQFO7Yq ʄb\Np3bxLrdQS"ΪĹZݠA "PUK3|o*J*Awe +ރаa-Zh! 8?d< 8s~d#F5}tPTzӦMQiI%̙3yrիWVdݳiHT!m9}2.Qҷ~o QnsV\;vOT-Fi>,O?oܸ&kI00cc̀ .uHA`db.v S "V/ҨQ#RTM6ogH9:{, .09%''ex<~爈W%{1Ws;?wIpA>F~[(. 6\,Π'狨 $8wӧL+p„ [^tۘŵT4rs*$a{BFyvis$,YrK "}azW a^Zz&' /7?q: fMĉ}YwE%lHl~?kz}:u +R'_*ɓ't2dl&''gĈ\Å3/'{1c)tI03<Û">Md(`^X´RJUt·!V w1HLSøSCk܉ʕ$/\ U;z,VSΥqϹR;tfLB[%Ti]2-X Pj ԭ[(ȑ#ׯT:qҎ;ꫯA}:rk1!6l؉'<=.~A)|v~W Dj8qJL|,*Wsba ,ڵ[n0K͝;{pSi֭Oz뮬,1N-Ծk ,Km(_zժUw}7S}5$}+6m$ށ7|s˖- r膕^!IhB$`EeYW&O?%tQ W_-h„ 0*6f?Ao6MתUmS9sD( J|i?cп&,%!y}[bEǥe7Q*8ف,ip]Y'^/p@O)Q=pkbEtg'v"tչz"PF-P\Xba0E]E =[b8bw-[f!޺}vRϧ0ru(/:ؔ/\pa.˖-[zb{Oý fgg?CΝw"5k֬J*طoߎ;ϙ3s?l}/B60w@l:(b;>:ujʔ)ϩsYZ=z7S*0&'ꏋafj70' N||<:2~ݾ}+̯;w.99R7o^v-1qsbBff7|GaraϮz~XZAAA^`:=z44<ɓ}Lᒁ6,L- ޱ{=fr x1ÝxٳgC,.Vae(9A],ݻw^_TThݺKǷzKdҰ8It%`6,]&EPtM60 A)5lذr0<;vlΝ0_ȧם:uBs x91 z>H&O,w}꿚4iI> 3H'\~f suԩS'++Z`Ǥ >E۷o/V +0cXy-%B6HX{reJ2y$͛77 w.^dd$j"X^A$T?nm% Jg`J4̪,vC.â"YA{kY&1D-Yv >snAoS.m[vO;ua(6z$ W~I g8tAs=^xh϶7(~g)bR-?[c{O8{sq&g:,CK.;z +vxn0֭pں!lܸh::~Oi5h`~~7'v ޽{}͏Nz _׮])u+Fw;mL֭ҥB^.իI4"kH'm۶_~?j-cq :ڸ`%1d~RR,{GcH/G` K$FK~@w4C򶄿:￷^Ė.`E:}t"{I[7`_|MG 6m[)`xIP8HxGbT@~R`ЀZNoa8`ܹs;#j!%zꩧۇ/=/=b7u(t_μ4OL8'B:Wv 5J3e4ɳ7MzǶ86iϱӧ59si3edޥ]g=| %M쒙ƼpocFzf͚0>WoVЍ sv .equbݽW6'!aS{s)lD>~n; nݺKLLka2.::ӕ{r$P"EcYtקq$fu K+W07s[$ٲeKxV#cƌG"إ֭[[l4h 2-A h7Vz1x5F.~i͚5 ƻ)mݶn:XWuǷM37 v @cVZ$HwG]>|<KX9͚5 V]͖'9`2Ϊ[MMߟWbEo$Ɂa-VWJ޽퉱-Fi" 7{|L]vHw "(uz(kֽGS" j6C_5@DN [ضktyQرcUB`ȑ`]̋+AuXtSmsf+"j (4Wg$311^zl1y7jQQFiiiȪmԢ/UDN^3a颖V^ajL]:<}IU;Fz12 VM\T|\\ܺuJV Z4R ĒmzKBcwW݇eM jnET܈C7cWrr2q6QK?K$Q粊:Avv6'A ٚ;vJ'5+Fidזr" O8/8N"oOロ?~0ńm,9 ;n"[hճRBW,0%Й(b2 ӊ,X@n/AфEW-Û5AiQ]f kf0vJEfϞr _nĺ~Xp$4ۓC ]ldC˘=H@+*!a@emog'P^B>"iSʰNΏj6UHd4>zMĹ C, mMQV3,MVڭf)XޫQP{k8S a.ȴ(gMlqʕ0ʮ-()5Iթ3o%4}cp~<_'>0MaQ0ټ˼gmFB:ӉQk~}ڴրmBPC%Zex E%INQ12/Dknc,gXͳTjt t6aJ*rAJy -WW7V1Q˽X-X}28O,a jGboHzHh˨@l:GͰo1kQ jJ_~ +0=Ů4I]utrWUR*yPf5jș";;;RFLHǝqj<\`6@o n} QF@-KvBTkNL1tKseUh3aa0LC!EFKYDsNL'(2O bB#55 P݌cdb$8cq&,Mx$##D~0)vO] T#AWHX4!k g,ZW]UV7lS޻vƖ cf«3-hnj iZD[n4PشiӰAD:q>`.En"mip3qs:#-6UǒD0ݻpVVmAׅ c4hin3.B3a@#a.9౰&*P#Mkk8eCtS7IN@+5]qhgp)5я /^u&z3|jAObj4WT+91-(h-;N:aÆx={v$G]H-KO) pe*my`t@M4n,QO蘑iDj/W?Z>}O_Ͳ>8fS R68BN&[l;CuX?tPFIAp8x6XO\禧scZ/z<gmt933oݾ}srr B"z4_vb_~nf֭{ݠAqq =RҺۋoea&ug$>f4вq+pF$<ѢYVQeY;Q,C)gp Uڃt(gOjqBGC;n، 5Q.B랚z 758E 9?y{VZl޶B\M5VTgmk%="CR^_4P?0Eg:F$)ծޯ~~Cj)~y}$ GH>Sqo_U;xCC p3b47,,=LYxIi>Mizئ.u_f$Z&IAiΟ/ۘr :vLlMS*GpC _DUhk4O7n&gRcAE^MA6H \/oLC aH*1}9-B((&ٸaZ]rQ>IUܵX֠2VL]RL0 IӤ7x'ˬDX.\j݄'!hԗB/H loq vXۙc`EEmؽX|fe2j=8FgHBg $VEGL}}piϽeTqaHӿW'NP4_2C0@Ir lŜ:V>}ԭ[ n:9Ez4Ԡ/~ю8'!~&0=C RrfҒEHEMPw߽뮻JKKI^OxpaKdͻnr6xtJjig4O,Xfaa^W_TOӀeΜ9)r&¬y{֎+ҐLiwcGs2 .LC m?\Tf۶K[v̈́\͝y M:|E]Ҭx-[2}/NWmsYǃ5OMƺM3g%\Ĝ8 'CMh@'@]{Kpt@ 9--ila&MuY|y&MHevliSӵ.7n^cg\vVp+VkYP԰30N#uSRZ5i,(ۤhem@ mk6/;|Xt;d ZkM}On]`.6/,`Oɋ>o޼;ϵSRhB@w[j )܉lʕK1_~%s"`ؚH9 1Iu{P~;r弜a2'O,TeӦM3Mjӏ}"{$ 6-YKE{(pk2]4ƛteZXWBMN OPs76D7| D_<9Q$a̪rhE#!^@e>PfhIM=РĮpp ݻzjބ8`'qZJرH`~EݻwAϬ /0e!)^]g" tS[`@虰 <3|juA7 =,*[=S#h}hն ק7Ԍ j+ #u3Q]-£ 3tW'#(jvV<+e͚|qC1Y:Ꝇ K~饗֯_?R7\K`єSrrZ |uvofRR ~zDՠʙsHÌV S֥@LI엔Ům߾<ZzG,DnuCˡF0ۀ4 h|C?2.?H|L$Mƙ,E NK}Y4Q:N߽inZqݝ[_HONN3f L&¾ΡJj$_߿eR*I ¢+U$a~h߾}v*((> 6;wwXA>Ç8tP,TUU\hgx*Q{*H&/Ҏ;p\;fĤ3'\7:i̯cqozJJR,Xp5@ f- Ǐ0` DУ5[Zz]+ y )FaƓM© jѡCӧp 2%#hM C4rG`غt9+K!]d7mrk3/26oMtĤnunC}8SkԶq ƚl#=nܸ!Cׯ?mڴ:K ɓWjLXAu o"Fn<^p]v';;~W^D,YoNiٜ$RJCF߿?]bϾ *SU?28m۶߾}ܹsᇕ+W[Hl"xTn׮ /tU/?ywV>Ϩp y͟?ժUMO?<^z)B᪣_w͚5sYp!xR5`gφ>pWt>ĐlӦM0H~Ai@~xAlhK.$~9>VDQFTG#=ZZ'h[#3  摙H ^|ajzLw0jos,.iX6@E*qdMQ-j(5(_r@?zH !4n@2ߔGCK( 0'W` LifS3 5s3ٽ{+VT`:u>|¹oُc˗/_T >5zhHnfr kQ]%aÆ۫@U@27o^%T2 ?7No}ΝU(mXsss>H3p#,+ xdÚYG|o냰<1cYuIKK\+jz)DEQQc)Vb.]~$@ml8n&&hPgz6WKM,\dY枚V?n]} 8Qhԙ&,4D&&`* oqkJ_ivq k]w”mCTB =¥ .י_ ۦxBӅLpyGs aY'Q&Sb .\ح[7`cU(~@y>D:'o[V3j}Tꥰwـ&%ؙZ4 gBu]v:tdERM6Ǐnk+ )l`gy&0͛7)>xyvl2r~8rþeO<Ѿ}{\TೕjB 3RV}9r#Z{me#$GX]G=饗;ɰBGo_=ܗ_~9F=x`ԃJ ߤ[J8R_+pCbFKg845őYf@biUB)2 -~i? TBn4⬞=w":9l9gS%tWȹ{キZha+UVGEAAA:u\*IO~ ڕ jX3G+g'剪p4wQHB9>}r(RqVa8.+ϓUav#UI&vYgպukȈZ_Jf: 1;v`YF V\rI5kvg*yՄNM|wTR7IǮ&6Q`ܶι3Q)G0 CG;ش"lqۤDFO[xjռi&vWrm 7Li<%pyl@ƭ兆,1`I[˺|u61S<ӴiSY),,ܿL:~U!ӧOߴiM7\9#?iTu\v/(akfffg0/8z` ctTtM&Mr)\y)$@FAb-M:{e˖`>3g<ӿ;aI] !;s҉h:z/^x{XhW_}Wf+Νۭ[o]vU"'9r:l g=:vظqc|zȑիW/\믿7oMHѣa%=1J% U"vHۇ~vCmӦ }bL7>#sʔ)_~oYV~ Խ{Hggg:#5lR|ذa{թLxU{==={rԃN2]nKY/1&ѶFo$̆9( "æn]mk2Ac@.TBw̟C=jՠ>r%HjAX`wIږ/_ϫlI]y:qgW>H6{lV۳:to<.Lmd)*p9sD_<8Gm^N8m7k-o{3"SC [^=܄PAC}Rj,~a'x"vaZ x pQ]v{ri {.jW۝_Gsrr /sGjau~<Rf ROrcA眻?vƥ?XCH.VDF-(lc(iu` TEU8j(9əwev.\v=|&#VD(clm۶<+lһwok޼yyMb=h 6mt̙ yuX"t' ٳUVm;k֬Xd9W;^ j>#w}wE[N6mZ&Ly PSm?ВЏ:tP} 6>A\Qj06?~J_-~-HO A Nc h)*w0_4Jf:Ė)1OQabߦ {ȑLO>.4^{mŲ)bO'$є"bG}Ǐz=jW^!Vݯ_|&':ux1.8M 38~"PSxpaɭ܊='AB*=z|'x,ǎ.;^d͚5#6mږ-[Ɯ7os=_ &LvoVȹN:_~$j lٲ~:xǧLB,w.2tu-\aÆDf͚{GUB`[dw }!555wyPF[n裏{y@/V+LBBB췻D5•|C s"!g.R+Cl:wx8gl҂^>z*Qۜ{M/2w$Fj߶.S  |""&,|&LmyV1B"gRr,G]`KcNoׂ!ڙ51n7&a ZDP FꪫGghi W_02 C.{LӔK= ݊ 2chÇ+n6w\Uk i^u7|3xgdQ бc>33So󴽺Xj+qҥF"- 7 3 Z ~`Ǐ׹S[jR4\9dɄQߐnM5:feS} ۶y;s *8ZE$PkMV_/jAKοdè,DAKZͻ뮻..}A\WGrmٶfMw9k{7)aظusKDt X&EdW^=bĈK/Z^h 7̓?|re_m{D`c :_3**\ne |nN: a„ -OMp=tgX* MU9眷~DvVȰk߾!EEE}\X@IIa#Y%k~M=xPmw\fV-Zz?kVnXXvMfZ2Z!vMbes!e+mca<򈺣9`I^ W^isIi UÉZ3eJ8OwsjQ.l.ɧ_0)g'? f5ybh6֑sgee\}[>gyF][m68tRRz嗫 !DK.HbG,B`M.eòmǒyuX֭[W xƯaӿKvvxUT!۷oQd0*ccAmJ}'1&RI[(^أ>w`0_cذaNM:k/c{\|ń[ި}?uT&L3 A?T̡QcƥSNDy+v)Q_Ws߿?:֭[ݙ#3fc`݂YǏosK>8xEzWnݺ~Ƞ999xŒ;vD-FmXuy;wVOB E8KEd6h&>%-;Kfp}?}j^ٴ]@`h|־}no߾-[DΨC%Kܷ~2)#`5!Dⷐ7ݡW9@|",2r/͐ uwXI@'MDbTh"Ҋn3 ҥKdG\%&&T ᆱyW ZDBԥa0l 6mڤJ9 VꙬ,i!FQ7 @]*˓WNNf͚ [4ǟtIrcb?={jX*jXLBkFrMS;Fq+v;xgS ny]u۴i/ %&QA'~JsF'kh{!{\Ra< )N2QDBÑEj{ԃm$ P= .4ED3Յ%8<*d$fZ} &gQх=t7oY" IDATeÁpqPخp7'\{%"/U0#L#T @ysXa <:ϞiʺBYO8־w^`A gi~ :Te+PfՍ 5>Sx })Ԕ\0QlFH䑬hu֩~58l0_F _P%VIeկҚ|'VVP#XclΪ-1vyHh ڷoⴡ2;5m1h0ҵS_ øCΣ$$$eڵ6md{X9@o6xպ /ܷoqB>i6hbPh> Ra7.U_JSbuƜiIA!%Ze~AMM#iT.'F@ZI;+1f(X,)B540s=X"2aML Z [k}4)]U#beaQ^j>p65Zj|@TR@/ta&b$^a 777WMp'@!:hٲ-|/r͟Եk!Xϛ7OSXU=e w*/4yX85x$U~Tg9ݻaz*n |iРR_x1:v8n8>a@k$O:)SfVǃA~/x$jӚA *T̤<ҸU.RvҏbpTc'>,AAjBEQf2L ߫${(LA K0 Py=iT$ݻPGUfy]3M6UZHԘ%2 Yni^V{z3f?աCa{ ɷz+QS]aSWx%I_.d׆ߞ={V8ѤI֭[>|Uw*l, VZZZ.]ԫ˖-#b\"ȏc;ϖq'xk׮65Ç\M\UvP3fL˖-mRomVۃ>_ieg@M73tT;N.!YF ye, &v! AÐ UW$.VZo{2暆s&>Xh(yE8閒hQ@eyZvJM 3j ֯_/~'ѿD$`W]u#hkbbg~0A'sJ#de̙iذ\ۄBVԛo{ ѣG;Q媂>Λ7ݜ4 auRhbǍ=u3x _&٦冿@ ˠ}꓅lx~=\fff͜ځɳ2۷iFR}h۶*Ν;>mۦJ%U<2[X4LJU-ZTx@1Gr=G}t[jE}~RBXO\sͲedL47|3)z+Z㸨 Yi [:`'ԩ4IPF,edb 8LKi]<*{T_5j4}t ᤓN/4 VevD bNAsS3M&1+ePoiev_/s@zLt1԰5ҸNH\Y?xSO}7'O+VXY7c m[̙3[+͂3.}T/[Z5֧z(zOUKD|ݻwG4;l0HDOGj!Cdw-XTLYI2AwGh/!r$УQWj' hy_`չs ~lOC|MX^wu˗/Wc n96mtѢEO>tb#/boM6 1=xkBXDps<[4JJL͹uFZI-[7HMӃ̈́Y6AJ+LznSNEof9ݏ|9E3 ˺jP@5hР4<٤I/^ ;C?E& &3EO3tqJu(w1 |)w#ںI&wb596-eI rai})5kdɒG}8|v\}f)y f;§ϝ~MnAg3 RrEyHy$=E t&yyy.( eO"Aǰdgg5jtg\F Ր> mڴ:u* /iӤ+F}7>1cB4WkC D}l؝(%m0jIB|RLXTk*=SFx, P˂||^,*&B KH*W-lTN:Νm>DOJJJL(wS ]SxpW $,^{55s=Dbxлw-[ۿF-u$`3"-fJH,V-Z-TU}dRaBU}Өn]6%}9"TCʖG~$9C vݱc HCے 8pl9\^?0 79Zhذas t|N&Oyf{= ,&LR;jXՂkx.aRV#D1h(K-P3Qc3GpLD F2'wމ>c/3\/^t~;ϟo&Jm~$k|v0%c3LHHM[]TS}W3qjmt "H~~~rT ??j*V1`j2 ׵є+Fbـ;. ǎNmSN﯒BmuUI{6lִgϞ$<%/G&pADRT[Me?6\Z_6W~iۏ&?հ!EȒZ)EG5uT}9|嗙nݺtAsM7Zs2\TDUz5ۇ gլY8yoII^0vPԪUcl$IoDS5m۶IhѢT^!M &*r}c@aڧO1z̈́S|ֺΔRd2#,& hăQzJXttbO+-5YYb9;{({FU!?%!HQPʩεiZ#*rS?f̘?Su#̙NС7krnM=3o<&̸NI*IIGT@ wYwܹU>6͢fl޺u*s.]mhUTĂ}\(=K|S7lM _,VH+n촲͂n DQ1E tZ¶Kꄪԑ5S,5#ݨ?=|~3a+vѣ}2+֮]o߾)v~GF7xeA5 ʩb C'NTW9((LE._ gϞ@< ?_/ɓU:=褓Nr&Szr),_poاz8tҫs3iiio%\2`uL^wXUӠ>ۀ O? ܸ)Ck< VUPc2T혩egCގsl(V#+ njjjϥ\5E]X5d.{V۷owdc4 6_~#Fka9r X/[otgc%K$&&ڊ~'e u$9Oǃ iAk&4)1[<.MmCsi}Kϼ`+},2-f´}Q./BRK#[۟<,U]NX8;|a9s \uP<{Ѹqc'y*,MDhLXip (>zUv*T?| g-tnF>܉&mIIIiiiNhe 9Fe; -,o ǂH}1b-3X!Q).z_aܱU.ܱg0luCd\j'1N AbGy&v출E@ Tz,q?y' :׽J0ڈBM>q&[ά}yLoysU.1:ݻwiii5jѢŬYb2ddն `͚5CDYH͘Y0-;,d%W䙜/ 3j}FG)՞ݲ~ E3 0)l;G-/m GVϴo.L{m3yJZl„ @dj-)^_5!ڤG5U >߿ր /,_ @}uZڵkOڛvٽ{wc4Y)ouÕ;;lذ /`k:F .-X@VZR}́-**kmmHCZCUzYf܃ PqIɦ;kh'c%(3|wן 6BÙ@'?Ovi"F$! fZ>u0h^qbk>}j1"ر࣏>ʮ֚ ]({)j1iMP0)1jo7|)1u#: yBGp?(do>;уlsm6 6e1 R/Yg`uPmr饗K,uv/$)l~RH_xcǎR)uYN(SLΊLb)!O%lr%J,\J[vi&MdlCɪ\U=bx`0Gw]Nz-gyXBM 6[c SNݽ{7'ovXK )8_ XA˨i?k433믿NIIq=.3qDj믿85koΜ9ovԢ+  $;uUذ@#umCͱKXPumʕNOL`&.PAo(ࡼƁD8ӂc>0hbл|F'"Q Iс\jفȠLY|JۊoutzӦMıCa3I ?tg@sk2k}4] /OV2dHVx 0PRR2mڴ=zkնXM#$0a.8>K/{n~̙3/ݻ;=={v֭ez ='2JпKX\#yE#@." yT7n$Hz5 ;3R9:e,l(ZĎƄ 0t7Ef, ڶmq=" ns$<٠Aѓahf魉zGu|.]xgl+y@&IK**uXn̙3Tt:tݭ[70wfg}6###b.dR%ƕ|~O;x Zq8&~1hO 0a-EP %Y|^xX%Eonjj׿k`? ǣ&x|W|zP_?hYf=+1IKl?wշ]*C؜m@(.]ڧOݙy}AzXFDIB(xjQNGgqPd- K|@x&-- R[O>Dh SO?t+۷oO\UDheD4n};q1{~ﱊ̛*E9_rMNg%bM zL !ւ#^8thSw qO {7mT[[b G~eZD-4ґΚDR 6w^43g$ d}삻75k'3Dٳ;oN<9jD+%p,]>;q<;vۘXHmʸǏ/X Z$ְ OQu,$wcZD=wΝ;ao.r糙hx,3d}nD%?9 By?\U]GO8z>zJK_X~CGnB>P jaZd9.ꡱ䦽^u⋁@]k/׷xWݣ|Vg}J̞j Z7NX։ԥZuDHۋ_ ycDIkWJG<(i["܈3"]]T|Hhl.TL[;PHr#I̶ͬ[eEQg2jzAYiƇ^`"1^.JVp '1IN"ݟz˓V+ R=^?}ndG"zy\gBj+e,+WḘJK{U<}õ]u\rLߤے%=^Y8 5RU-Kg@s9\-F 1BS爥Lz!c#5a6>zvג$;dww86R@TF̧̠7de!ɛԿ"AԄ ~me9ON&:J\Hm  !a<=kMs0Q8!S  2OaxS( 'Mzľr 86k{5EU  rП GI#q["RJ"=rKV^JR"AŬ:zGBE*Q~j AA&Yi*A4N,b&>NlLM{5qZ\_Xe$x0  2(>ֱ~ |]D}2XIcP0d60 )_<8Bޙt&ԴuNn  2t:+s _pA +Մ?gb\)׎'߉ZEC9  r0 &/FZ__xJKKsssS(V+u׺D S ̡uwsƲP&eBqƪ*˒}>ʕ+_}U'YrmAʈ evC„#[Ke;v_tG˿/ܠkz~_R# 9dBP#  q ʧ~3jq>ϝQF\,=yf;di&61)09d¯J WtTp5S Lʦ]j o]d/wGQN#'E  2gU/XB0|W^]tiWW*J|ݸuÒ!ABPVk.#r( Z:[Kkv;:˰-ZT^^xÇ;띦Ĵ*KN<TH8S0ʦ|6|sE &ufr"=GEU  2dgah͛7wtt( ԼŽk'qom& f45XSKf@gpA:FťMEuۮ r޼y12TG-N[USޮ6 m)t+g2tEN q=U׻s_z%Vqe շ۩PC\aGC槡LXގ|ń5  HҟڱXCۦ{GJ &+:91ŒzʻPՒZJ]I fHpKPΈⱹ Fң-*\ w *lzf1cS#ČK&-":K$  -?9H\4nr|>rSҖ䘠e)שwҔYYsrt01#p[rU\z=OT޼<ַ˵was 9a2 \:_(97)Y)DAA R03glՆ(|P(ʆA YQ{hI7 T*j" Bg`|9k+Wtե<3:zTH8TNA$%1kXZV SQͩT\b1}AA es=GOik}R혬%8sI1gl5R-*}- 9ɐ2f<&~YXLt~sV۶m[dӼe˖mݺ5~˅,gr&, CϹrAO%KDģN|  axꩧ*++Ip[lyUXuV&`J28iiQ&'aJ bxÄ=_t,NvEiz5u'څʥ4YSͥcƹ@AAHXuر$k= o {n4 5ePZS -cBNӧĉR$V~p:ò6_تpB !BFƉ?z  C$5555wyyy˗/=zt"vHKMA,!#X/ʣO𚄘IJKi*8h?pRW ))*0AY  2p:} [W(/HH!"r ͓&N7g }TrEXGi  2Z: (֞MZ[B"<̯([0x~I}Q;Aa  L IENDB`^> 666666666vvvvvvvvv666>66666666666666666666666666666666666666666hH6666666666666666666666666666666666666666666666666666666666666662 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH @`@ NormalOJQJ_HmH sH tH H@H : Heading 1$h@&^h`5D@D  Heading 2$@& h5PJ@@@  Heading 3$@& h>*:@:  Heading 4$@&5>*L@L  Heading 5$$d,<@&a$6CJDA D Default Paragraph FontVi@V  Table Normal :V 44 la (k (No List 0O0 Head5CJ 00 1.^`00 a.8^8`2O"2 (1)>^`>@O2@ ReferencesB^`B>oA> SuperscriptCJH*OJQJ4 @R4 Footer  !:)`a:  Page Number CJOJQJ6Or6 Grade`^``00 TX0^`044 Stage p 88 iv.dh^`.B. Body Text>O> :Head 2$<&d5CJPP Checklist 2  88d^8`0U`0 Hyperlink>*B*JO!"J i.  p0d^p`0 CJOJ QJ LC@L Body Text Indent L^`LVOV Checklist head!d h8 CJOJQJho"h Text" h8p @ %B*CJOJQJ_HmH phsH tH @V`1@ FollowedHyperlink>*B* VR@BV Body Text Indent 2$d^`4@R4 Header % !5VS@bV Body Text Indent 3&hdh^h`@@r@  Balloon Text' CJOJ QJ B'`B 6Comment ReferenceCJaJ6O6 Head 3 )$$a$68@8 -6 Comment Text*CJ@j@@ 6Comment Subject+5\jj  Table Grid7:V,0,BoB *0Comment Text CharOJQJ`o`L 0Light List - Accent 31.OJQJ_HmH sH tH DZ@D 0z0 Plain Text/PJaJmHsHtHRoR /z0Plain Text CharOJPJQJaJmHsHtH\`\Z0Dark List - Accent 31OJQJ_HmH sH tH z@"z  S Medium Grid 1 - Accent 22d^m$CJOJPJQJ^JaJ"o1" `pagesd`Bd5 0Medium List 2 - Accent 24OJQJ_HmH sH tH HORH  E Table Text5CJOJPJQJ^JaJDObD 5title6dd[$\$CJOJQJaJBOrB 5desc7dd[$\$CJOJQJaJHOH 5details8dd[$\$CJOJQJaJ / 5jrnl^o^}0Dark List - Accent 31:OJQJ_HmH sH tH |O| } Medium Grid 1 - Accent 21;d^m$CJOJPJQJ^JaJfof}0Medium List 2 - Accent 21<OJQJ_HmH sH tH D`D@]0Revision=OJQJ_HmH sH tH PK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭V$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3N)cbJ uV4(Tn 7_?m-ٛ{UBwznʜ"Z xJZp; {/<P;,)''KQk5qpN8KGbe Sd̛\17 pa>SR! 3K4'+rzQ TTIIvt]Kc⫲K#v5+|D~O@%\w_nN[L9KqgVhn R!y+Un;*&/HrT >>\ t=.Tġ S; Z~!P9giCڧ!# B,;X=ۻ,I2UWV9$lk=Aj;{AP79|s*Y;̠[MCۿhf]o{oY=1kyVV5E8Vk+֜\80X4D)!!?*|fv u"xA@T_q64)kڬuV7 t '%;i9s9x,ڎ-45xd8?ǘd/Y|t &LILJ`& -Gt/PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!0C)theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] d>>>E>> 2P]jn""L  ! Sai #I&(*,.H1t479%@ BfGIMSY\_Tdux5|v̅1--00GJRVWY\^acefhikmnpqstuxyy A   !#F'+/28@JTMWcXXXY/YYYZZ\^hq:x },E-00HIKLMNOPQSTUXZ[]_`bdgjlorvwz{|}~PWY]dfLSU !!X!!!!@ @H 0(  0(  B S  ?_GoBack??@E@D%")"""11111155;;<<==CC1G5G8GtBtItuuuuuuovuv-w3w8wAwhynyyyzzrzyzzzzzz{i{p{{{{{w||||R}Y}}}}}~ ~~~~~34679:;<>?ABCD.9<?*."vpu9?7:HNjo}####%%e(i(((((;,<,[,\,m,n,,,//11111111@2D285@5B6D66699<<==@@DD8G?ABCD <?33333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333nors Rb__ $Jqs  *ttuuQQ{{W#%%D%%&&&&&&&&%&%&&&&&3&3&=&=&>&>&H&H&I&I&S&S&T&T&l&&&&&&&&&&&&&&&&&&&&&&&&&&'#'''''''''((((((a(a(u(u((((((()B*--3333444455999999;;<<_>_>CC'CDDIIOOPPPPvPvPPPRRUU)n3n8n9n3q3q9q9qSqSqTqTqqqirjr34:;BCzv~.9?''*)*)A)A)999999;;C'CIIRR3q3q9q9qqq3? P =\`09ƈg9ΨD>c8DB7Jc8Dg9                                                                                           $K^51^zj gPiLj Y#(iLzPy{EVfH oCN~=2!Li$#(Blz\C+y-,B[y-Zbsh:0h51J:se2*?/X7f2 $8:"9SAh7My{EgPiEPh7MVfcOSA*?/XcOB[CZbshiEhH oJ:se2Blz:0I2|,N~Y2.aAqej[ p U]  t V pJP X u6 B 3E Se g   5 5Z ; L #fOVRJoo !8d:prz?A*R\' C8WsuRZ27B]d0tw/C6T?<|Yy!0A?p|YkrQ:Ar: L m b!h!N"`m"r#Q#:#c##$&>&U&[&_&5x&K'^'`(v.*bJ*^* =+r+w+.G-]-N./20J0=P0>|0J162k2s2e3Hj3^5v6o8*y8({8(9N9bs9 ;2;O9;g<s=}=S>T>7?O?@U@e@x@|@ Al.AgBEBzB"CVCtdCBoC DbDnfD E6EFZ3F7F$GhGHHHy\IunIGJuJHJ\JgKkL=NW@OHO2yOHP%PAQ&'QRSSU UVW0WyWX+ YhCZEZ[=[#8\<\^p^ _)f_k_G`a!a bbtbvcc3cCDcGc.[c[c9dZ9dkDd[de-ebef-6g]gm`gng'h0h;hi*ijt2j7jnjk;lTlmhdm6nGnI"o0o;og.prr.@sTs}0tyftsyt u4/ueavP!w;yiys2zj{X ||1&|L|}>~&Q~`W8v-$){5U65@#I@]_\uFo?5Cl2 @S^L/7@VSWWaeoy~[LD=7FPU1\UZZdY}0Nb9:*58hsr'I SaM3cu{q<[<cMU!IDU# ?F 4`YWXw}]>x*+4F`p.+ C/at|i-{{4gfsAq-~*'dc R\dBQE|ns+6p@"*P:T_i+qgz#DqOUEYBvxz {H 4Rx(]Vv@ *1p<?8cXnacl-Mu?!l>NtdPeJ-0gS@oq8Hc>-YGG8Ow?KMjcrw?+G?Nh@#04$7DD@7=xI2JMQ4%,Zi5h:|RZhoh7} f )b`jqbxvZerhq\fb?ikv w~fE/70vI4M2+Qd'0mHWLhITzp2q[(Wp`(Dmr8d;t{#I=yY46__Grammarly_42____i__Grammarly_42___14H4sIAAAAAAAEAKtWckksSQxILCpxzi/NK1GyMqwFAAEhoTITAAAATH4sIAAAAAAAEAKtWcslP9kxRslIyNDY0NDKysDA2MTM2tjQyNLFU0lEKTi0uzszPAykwtKgFAFPi/UgtAAAA@iriririr345789:]D]E\>@<>@B@F@R@X@UnknownG*Ax Times New Roman5Symbol3. *Cx Arial7@Cambria;(SimSun[SO7. [ @Verdana7.@Calibri3*Ax TimesE.Century GothicCAdvTT5235d5a9IAdvTT5235d5a9+fb= AdvP4C4E595. .[`)Tahoma_Caslon 224 BookCourier New_Caslon 224 BoldCourier New5Mangal?= *Cx Courier New;WingdingsA$BCambria Math"hXkh'rA#"m A"m A!243qXZ ?b[2!xx CAP Cancer Protocol Vulva College of American PathologistsDoug Murphy (s)8         Oh+'0 ,8 X d p |CAP Cancer Protocol Vulva$College of American Pathologists Normal.dotmDoug Murphy (s)35Microsoft Office Word@,@N@Dv @c83 "m՜.+,D՜.+,d  hp  $College of American PathologistsA CAP Cancer Protocol Vulva Title 8@ _PID_HLINKSA;4#http://www.cap.org/cancerprotocols  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHJKLMNOPRSTUVWX]^aRoot Entry F!U83`@Data u1TableXfWordDocument >SummaryInformation(IDocumentSummaryInformation8QMsoDataStorebR830MS83D1EAO1LRNJXU0==2bR830MS83Item  PropertiesUCompObj r   F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q